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INTRODUCTION
This century has witnessed several spectacular developments in the 
field of pharmaceutical sciences especially in the drug delivery systems. 
The newer drug delivery technology has received an increasing attention in 
the  face  of  growing  awareness  that  drugs  are  excessively  toxic  and 
sometimes  ineffective,  when  administered  or  applied  by  conventional 
means.  Thus,  conventionally  administered  drug  formulations  such  as 
tablets, capsules, injections and oral liquids that are administered as multi-
doses usually produce large fluctuation of drug concentration in the blood 
stream. 
The impetus  for  the  development  of  newer drug delivery  system, 
apart from therapeutic efficiency, is the cost. The developmental cost of a 
new drug may be about $250 millions (Rs. 900 crores) and takes about 12-
15 years to reach the market. An existing drug molecule can be developed 
as a newer drug delivery system in half the time, with 20% cost of new drug 
discovery. 
A wide variety of newer drug delivery systems have been designed 
and  evaluated.  This  technology  is  applicable  to  many  type  of 
pharmacological  agents  and  in  many  therapeutic  situations,  namely 
hypertension, asthma, arrhythmias, diabetes, fertility control, peptic ulcers, 
rheumatoid  arthritis,  angina  pectoris,  cancer,  depression,  menopausal 
syndrome etc. newer drug delivery systems represent a means by which a 
pharmacologically  active  moiety  may  be  continuously  delivered  either 
systemically or to a target site in an effective, reliable and safe manner. 
They  are  capable  of  better  performance  than  conventional  delivery  by 
monitoring the concentration, location and duration of drug action. 
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Historic development of T.D.D.S 
The potential of using intact skin as a part of drug administration to 
the  human  body  had  been  recognized  long  back  as  evidenced  by 
development  and  extensive  use  of  medicated  plaster  for  many  decades. 
Historically, the medicated plasters could be viewed as the first application 
of the idea of Transdermal drug delivery, bringing medication into close 
contact with the skin, through which drug is delivered trandermally1. The 
use of medicated plasters could be traced several hundred years back to 
ancient china. Several Chinese medicated plasters are still available even 
today in the market and regularly used for medical treatment. This early 
generation of medicated plasters often contains a combination of extracts 
from several herbal drugs, which are used mainly for localized medication. 
The medicated plasters have also been very popular in Japan and 
may are available as over the counter (OTC) pharmaceutical dosage forms, 
commonly called cataplasms. 
Medicated plasters had also existed in western medicine for several 
decades. In the United States, the following three medicated plasters have 
been listed in official compendia (NF 1946, USP 1950) namely belladonna 
plaster (local analgesic), mustard plaster (local irritant) and salicylic acid 
plaster (keratolytic agent). These plasters are rather simple in formulation 
and were development mainly for local medication. 
Development in transdermal drug delivery 
The skin was though to be an impervious barrier. At the turn of the 
century, during world war II, munitions workers experienced fewer anginas 
attacks while working with nitroglycerin. This has challenged the traditional 
belief that the skin is a perfect protective barrier and also triggered intensive 
research activities to study the feasibility of transdermal drug delivery for 
8
systemic medication2, 3.
Several  transdermal  drug  delivery  systems  (TDDS)  have  recently  been 
development  with  the  aim  of  accomplishing  the  objective  of  systemic 
medication  through  the  transdermally  controlled  delivery  of 
pharmaceuticals.  The  potential  of  TDDS  was  first  demonstrated  by  the 
successful development of a scopolamine releasing TDD system in 1981 
(Transderm- Scop system, Ciba) for 72-hour prophylaxis or treatment of 
motion  induced  sickness  and  nausea,  then  by  the  marketing  success  of 
several nitroglycerin releasing TDD systems of once – a- day medication of 
angina pectoris4, Clonidine – releasing TDD systems for weekly therapy of 
hypertension5 and Estradiol- releasing TDD systems for twice a day week 
treatment of post menopausal syndrome6. The other marketed TDD systems 
are given in the table-1. 
In addition to the currently marketed formulations,  new drugs are 
being  formulated  using  transdermal  systems  because  of  the  inherent 
advantages of administration by this route.  Buspar,  an anti anxiety agent 
and the combination of nicotine and mecamylmine, for smoking – cessation 
therapy are being developed for TDDS and are currently undergoing phase 
III clinical trials.
Skin structure and barrier properties 
Skin  is  the  most  readily  accessible  organ  in  the  body.  Its  chief 
functions are protection, temperature regulation, control of water output and 
sensation.  The  skin  of  an  average  body  covers  a  surface  area  of 
approximately  2  sq.  mts.  in  most  adults,  varying  in  thickness  from 
approximately 1.5 to 4 mm and weighing approximately 2 kg.
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Table – 1: Commercially available transdermal therapeutic systems  
Drug /Manufacturer Trade Name Duration Type of System Therapeutic use
Scopolamine -Alza/Ciba Transder  Scop 2 days Reservoir Alleviate Motion Sickness 
Nitroglycerin
Alza/Ciba Transderm-Nitro 1 day Reservoir Treatment and prevention 
Hercom NTS Matrix Of angina 
Searle Nitrodisc Matrix
Key Nitro-dur Matrix
Wyeth Deponite  Sandwich 
Isosorbide dinitrate 
Nitro – electric industrial Frandol Tape  1 day Matrix Treatment and prevention 
Clonidine Of angina 
Boehringer/Ingelheim Catapres-TTS 7 day Reservoir Treatment of hypertension 
Estradial 
Ciba –Geigy Estraderm 3 day Reservoir Relief of post menopausal 
Symptoms
Nicotine
Alza Nicoderm 1 day Reservoir Aid is smoking cessation 
Ciba –Geigy Habitrol  Matrix
Parke –Davis Prostep Matrix
Fentanyl
Janssens Duragesic  3 day Relief from moderate/ severe pain 
• Information not available 
• This product is available in India (Transderm-TTS; CIBA-GEIGY; Top nitro FULFORD (India)]
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• This product is very recently launched in India. 
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It receives about one third of the blood that is circulating through the 
body7.  Skin consists of two parts; the cellular outermost layer, epidermis 
and  the  relatively  a  cellular  connective  tissue  matrix  dermis  (Figure:1) 
Lying between these two layers is a sub- microscopic structure, the basal 
lamina, which is derived from both the epidermis and the dermis. It serves 
as an anchoring structure by which the two layers of skin are held together.  
The  blood supply  to  the  skin  resides  exclusively  in  the  dermis  and the 
nutritional requirements of the epidermis are met by diffusion. 
The  epidermis  is  composed  of  two  parts:  the  living  cells  of  the 
malphygian layer and the dead cells of the horny layer (stratum corneum). 
Epidermis is composed of four cell types; keratinocytes, which constitutes 
approximately  80%  of  the  epidermis;  melanocytes,  the  source  of  the 
melanin pigment which gives the skin gets its colour and protects form the 
damaging effects of UV radiation; langerhans cells, which are the outmost 
arm of the immunologic system and serve in host defense; merkel cells, 
which  are  thought  to  function  as  mechanorecptors  for  the  sensation  of 
tough. Keratinocytes organize into strata within the epidermis form inside 
to outside, stratum germinatum, stratum spinosum and stratum corneum. 
The stratum corneum typically comprises 10 to 15 cell layers and is 
approximately 10mm thick when dry. This membrance consisting of dead, 
anucleate, keratinized cells embedded in the lipid matrix,  is essential for 
controlling the percutaneous absorption of most drugs and chemicals. The 
barrier nature of the horny layer depends critically on its constituents, 75-
80%  proteins,  5-15%  lipids  and  5-10%  unidentified  material  on  a  dry 
weight  basis8.  The  protein  fraction  predominantly  comprises  of  keratin 
filaments which are cross – linked by inter molecular disulfide bridges9. 
The lipid domain is comprised of an organized distribution of intercellular 
lamellae derived form intra cellular granules secreted during the epithelial 
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differentiation process10. 
The  dermis  is  3  to  5  mm thick  and is  composed of  a  matrix  of 
connective tissue in which predominant bundles of collagen fibrils interlace 
with  elastic  tissue  and  sparse  reticular  fibers8.  The  dermis  encloses 
cutaneous  appendages  (eccrine  sweat  glands,  apocrine  gland  and 
pilosebacious  units)  and  is  penetrated  by  blood  vessels,  lymphatics  and 
nerves. 
Figure 1. Simplified structure of human skin, with potential routes for 
drug permeation indicated.
The blood supply thus keeps the dermal concentration of a penetrant 
usually very low and the resulting concentration difference across epidermis 
provides the essential driving force for transdermal permeation. 
The  fatty  subcutaneous  tissue  merges  with  the  over-lying  dermis. 
The hypodermis supplies a layer of adipose tissue over most of the body 
that  provides  thermal  insulations  &  mechanic  protection.  It  carries  the 
principal  blood vessels  and nerves  to  the  skin and may contain sensory 
pressure organs. 
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Fundamentals of skin permeation. 
A systematically active drug that will reach a target tissue for from 
the  site  of  drug  administration  of  the  skin  surface  must  posses  some 
physico-chemical properties that are capable of facilitating the sorption of 
drug through viable  epidermis  and also uptake of  the  drug by capillary 
network  in  the  dermal  papillary  layer.  The  sequence  of  transdermal 
permeation of the drug is shown in Fig.2. 
The  rate  of  the  permeation,  dQ/dt  across  the  skin  tissues  can  be 
expressed mathematically by the following relationship11. 
dQ/dt=ps (cd-cr)----------------(1)
Where cd and cr, respectively the concentrations of a skin penetrant in the 
donor  compartment  (e.g.,  the  drug  concentration  of  the  surface  of  the 
stratum corneum) and in the receptor compartment (e.g. Body). Ps is the 
overall  permeability  coefficient  of  the  skin  tissues  to  the  penetrant  as 
defined by  
Ps=Ks Dss/hs
Where Ks is the partition – coefficient for the interfacial partitioning of a 
penetrant molecule form the solution medium or a transdermal therapeutic 
system on to a stratum corneum; Dss is the apparent diffusivity for the steady 
state diffusion of the penetrant molecule through a thickness of skin tissues; 
and hs is the overall thickness of the skin tissues. 
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Figure 2: Multilayer skin model showing the sequence of 
transdermal permeation of drug
Analysis of eq. 1 suggests that to achieve a constant rate of drug 
permeation one needs to maintain the drug concentration on the surface of 
stratum corneum (Cd) consistency and substantially greater than the drug 
concentration in the body (Cr) i.e., Cd > Cr; under such a condition eq.1 can 
be reduced to 
dQ/dt = Ps Cd
The  rate  of  skin  permeation  dQ/dt  becomes  a  constant,  if  the 
magnitude  of  Cd remains  fairly  constant  throughout  the  course  of  skin 
permeation. To maintain Cd at a constant value, it is necessary to make drug 
release at a rate (Rd) that is either constant or always greater than the rate of 
skin  uptake  (Ra)  i.e.,  Rd >  Ra.  By making Rd greater  than  Ra,  the  drug 
concentration on the skin surface (Cd) is maintained at a level equal to or 
greater than the equilibrium (or saturations) solubility of the drug in the 
statum corneum (Cse) i.e., Cd > Cse, and a maximum rate of skin permeation 
(dQ/dt)m , as expressed by equation (2) is thus achieved. 
(dQ/dt)m = Ps Cse ------------------------(2)
The  other  mechanism  of  permeation  involves  diffusion  through 
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shunts particularly those offered by the relatively widely distributed hair 
follicles and eccrine glands12.  Typically one square centimeter  of human 
skin yields 10 hair follicles,  15 sebaceous glands and 100 sweat glands. 
However,  the  appendages  provide  a  small  fractional  surface  area  of 
approximately 0.1% of the total area. 
Recent  studies13 indicate  the  importance  of  appendages  in 
percutaneous absorption. The appendageal route may be more significant 
for ions and large polar molecules14, which slowly permeates through intact 
stratum corneum. The major fraction of most diffusants permeates across 
the bulk of the intact horny layer. The two potential micro pathways serve 
the stratum corneum through the transcellular and intercellular routes. 
The principal pathway taken by the penetrant is decided mainly by 
diffusants’s partition coefficient. Most of the diffusants permeate by both 
the routes15. The intercellular pathway is considered to provide the principal 
route and the major barrier to the permeation of the most drugs16. 
Technologies of transdermal drug delivery systems
Several  techniques have been successfully  developed to provide a 
mechanism of rate control over the release and transdermal permeation of 
drugs. To be precise, there are two concepts in the design of TDDS namely 
skin  controlled  device  (monolith  type)  and  system  controlled  device 
(reservoir type). The others are extension of these two concepts. 
Skin controlled device: (Monolith or Matrix System) 
It is designed to rely on the skin to control the rate at which drug 
diffuses  into  the  body.  Skin  controlled  devices  are  typically  monolith 
systems that incorporate a drug in matrix layer between frontal and backing 
layers.  The polymer matrix controls  the release rate (Proportional to  the 
square root of time), Which is generally greater than the permeation rate 
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across the skin. 
System controlled device: (Reservoir or Membrane System) 
The transdermal system providers the majority of the control of the 
rate of drug input to the body. System controlled devices contain a rate 
controlling membrane and the drug (usually in liquid or general form) is in 
a  reservoir,  backing,  adhesive  and protective  layers  are  other  functional 
components  of  the  system.  This  type  of  system is  beneficial  when  the 
desired rate of drug transport is considerably less than that through the skin. 
Polymer membrane permeation – controlled systems
In this system, the drug reservoir is encapsulated in a compartment 
molded  from  a  drug  impermeable  backing  layer  and  a  rate  controlling 
polymeric  membrane (Fig.  3.a.).  In  the  drug reservoir  compartment,  the 
drug particles are either dispersed in a solid polymer matrix or suspended in 
an  unleachable,  viscous  liquid  medium.  On  the  external  surface  of  the 
Polymeric  membrane,  a  thin layer of drug compatible adhesive polymer 
e.g.,  silicone or  polyacrylate  adhesive,  is  applied to  provide an intimate 
contact between device and skin surface. Several TDDS formulations have 
been marketed from this technology e.g. 
• Transderm – Scop (Ciba /Alza) 
• Transderm – Nitro (Ciba / Alza) 
• Estraderm (Novartis) 
• Nicoderm (Alza) 
• Catapress – TTS (Boehringer/ Ingelheium) 
• Duragestic (Janssens) 
Matrix diffusion - controlled systems
The  drug  reservoir  in  this  type  of  devices  is  formed  by 
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homogeneously dispersing the drug particles in a hydrophilic or lipophilic 
polymer and the medicated polymer is then molded into a medicated disc 
with a defined surface area and thickness. This medicated disc is then glued 
to a base plate, which is sealed to a drug impermeable backing (Fig.3.b). 
Most of these systems do not have an adhesive overlay but instead posses a 
peripheral adhesive ring. e.g 
• NTS (Hercom) 
• Nitro – dur (Key) 
• Prostep (Parke – Davis) 
Adhesive diffusion controlled systems
In this,  the drug reservoir is formulated by directly dispersing the 
drug in an adhesive polymer on a flat sheet of drug impermeable backing to 
form a thin drug reservoir layer (Fig. 3.c). Layers of non-medicated rate 
controlling adhesive polymer of constant thickness (Fig.4C) are applied to 
produce an adhesive diffusion – Controlled drug delivery system. e.g 
• Deposit (wyeth/Schwartz) 
• Frandoltape (Toaeiyo) 
• Minitran (3M Riker) 
• Habitral (Novartis) 
• Nicotinell (Novartis) 
Micro reservoir / micro sealed controlled systems
These  systems  are  a  combination  of  the  reservoir  and  matrix 
dispersion  type  drug  delivery  systems  (Fig  4d).  In  these  systems,  drug 
dispersion  is  prepared  by  suspending  the  drug  in  an  aqueous  polymer 
solution  and  then  the  drug  suspension  is  dispersed  homogeneously  into 
lipophilic  polymer by high shear  mechanical  force,  to  form microscopic 
spherical  reservoir  with  the  drug  entrapped.  This  unstable  dispersion  is 
18
stabilized by cross- linking the polymer chains by the addition of polymeric 
cross – linking agents.  This matrix is then attached to an adhesive foam 
(flexible) backing. The System has a peripheral adhesive ring.
Eg. Nitro disc (G.D. Searle) 
Advantages and limitations of T.D.D.S 
Advantages of TDDS 
• Avoids vagaries associated with gastro – intestinal absorption due to 
pH, enzymatic activity, and drug food interactions.
• It is a substitute for oral route 
• Avoids  first  pass  effect  (drug  deactivation  by  digestive  and  liver 
enzymes) 
• It avoids the risks and inconveniences of i.v therapy 
• Provides predictable extended duration of activity 
• Extends the activity of drugs with short half – lives 
• Multi day therapy with single application 
• Provides capacity to terminate drug effects rapidly 
• Rapid  identification  of  medication  in  emergency  eg.,  non-
responsible, unconscious or comatose patients. 
• Minimize inter and intra patient variation 
• Provides suitability for self-administration. 
• Reduces daily dosing, thus improving patient compliance.
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Figure 3: Different Types of transdermal delivery systems
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Limitations of TDDS 
• TDDS cannot be used for the drugs 
• Limited time that the patch can remain affixed 
• Variable  intra-  and  inter  individual  percutaneous  absorption 
efficiency.
• Skin rashes and sensitization.
• Bacterial and enzymatic drug metabolism under the patch 
• Complex technology / high cost 
 MATERIALS AND COMPONENTS 
The various materials used in TDDS are on the basis of functional 
classification  of  the  various  components.  The  basic  components  of 
transdermal devices are polymeric matrices or reservoirs, drug, permeation 
enhancers and other excipients.
Polymers for transdermal delivery
The polymer controls the release of the drug from the device. The 
following  criteria  should  be  satisfied  for  a  polymer  to  be  used  to  a 
transdermal system. 
• Drug solubility and diffusivity in the polymer. 
• The desired drug loading and its effect on polymer integrity. 
• Compatibility  of  the  polymer  with  necessary  excipients,  such  as 
solvents and skin permeation enhancers for the drug. 
• Skin  compatibility:  the  effect  of  moisture  occluded  under  the 
polymer formulation. 
• Mechanical  properties:  softness,  flexibility,  conformability  to  skin 
and mechanical integrity. 
• Ease of fabrication. 
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• Toxicity and purity i.e., compliance with safety requirements of the 
FDA.
• Cost and availability. 
• It is rare to find a commercial polymer that satisfies all the above 
criteria  for  polymer  selection.  Hence  various  techniques  have  been 
employed  to  modify  the  polymer  properties  and  thus  drug  –  release 
rates. 
• Cross linked polymers: The higher the degree of cross-linking, the 
more dense the  polymer  and slower the  diffusion of  drug molecules 
through the matrix cross – linking may be achieved chemically using 
cross – linking agent or by irradiation. This approach has been applied 
to the preparation of the nitro disc system17, 18.  
• Polymer blends: The blended polymer combines the advantages of 
individual polymers. The potential advantages include easy fabrication 
of  devices,  manipulation of  drug loading and other  device  properties 
such as hydration, degradation and mechanical strength. 
• A number of patents have covered the use of PVA & PVP blends but 
only  nitro-  dur  System has  been commercialized  and  marketed.  The 
system was fabricated from polymeric  matrix  made of  PVA, PVP & 
glycerol as plasticizer. The selected patented polymer blends of PVA & 
PVP are given in the table. 
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Patented blend formulations of PVA & PVP for matrix devices19, 20, 21.
Sl. No Patent No Drug Recipe (%)
1) 4,438,139 Estrogen
1-60 Plasticizer
6-30 PVA
2-30 PVP
2) 4,542,013 Nitro Glycerin
2-25 Plasticizer
10-40 PVA
2-15 PVP
3) 4,460,562 Propranolol
1-60 Plasticizer
6-30 PVA
2-30 PVP
Plasticizers: Plasticizers  are used to reduce the stiffness of the polymer 
backbone there by increasing the diffusion characteristics of the drug. In 
selection  of  plasticizer,  care  must  be  taken  to  select  a  material  that  is 
biocompatible.  Commonly  used  plasticizers  are  polyethylene  glycol, 
polypropylene glycol, glycerol, dibutyl phthalate and dioctyl phthalate.
Commonly used polymers in T.D.D.S. 
Polyisobutylene 
Polyisobutylene22 (PIB)  is  a  highly  paraffinic,  non-polar  and 
amorphous  hydrocarbon  polymer  composed  of  essentially  straight  chain 
macromolecules.  Physical  properties  of  PIB  change  gradually  with 
increasing molecular  weight,  the  lowest  molecular  weight  being  viscous 
liquid. With increasing molecular weight. It forms elastometric solids. PIB 
is soluble in hydrocarbon solvents and insoluble in polar solvents, because 
of low glass – transition temperature flexibility and oxidative stability. 
Poly acrylates
Copolymers  of  acrylic  and  methacrylic  acid  esters  can  be  most 
suitable for use as drug /  polymer matrix.  Acrylate polymers,  which are 
moderately  polar,  colorless  and  transparent,  have  excellent  chemical 
resistance, plus thermal, light and oxidative stability. 
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Polysiloxanes 
Poly siloxanes23,  24 also referred to as silicones, are organo silicon 
polymers having si-o-si bonds along the main chain and an alkyl group (R) 
attached  to  a  significant  proportion  of  silicon  atoms  by  silicon  carbon 
bonds.  These  silicones  have  outstanding  thermal  and  oxidative  stability, 
chemical inertness and very low surface tension. 
Hydrogels 
Hydrogels25,  26 are water swollen but water insoluble cross – linked 
networks of hydrophilic  polymers.  They can absorb water by more than 
20%  of  its  dry  weight.  Hydrogels  are  prepared  by  free  radical  co-
polymerization  of  hydrophillic  monomers  such  as  2  hydroxyethyl 
methacrylate, N-Vinyl -2-Pyrrolidone or acrylamide with small amounts of 
a di  functional monomer such as ethylene glycol dimethacrylate and the 
polymerization is carried out in aqueous medium. The drug/hydrogel matrix 
can be prepared by either incorporating the drug in aqueous polymerization 
mixture or by a process of equilibrium of the hydrogel in a concentrated 
aqueous solution of the drug. 
Polyvinyl pyrrolidone/ Polyvinyl alcohol. 
Poly vinyl pyrrolidone27 (PVP) is a white odorless and hygroscopic 
powder. It is available in different viscosity grades, identified by K value. It 
is soluble in water and in any organic solvent. Poly vinyl alcohol (PVA) is a 
cream coloured granular powder and is prepared from Poly vinyl acetates. 
PVA  is  available  in  different  grades  and  the  viscosity  is  directly 
proportional to its molecular weight. Both PVA and PVP are non-toxic to 
skin and incompatible with inorganic salts. 
Ethylene vinyl acetate (EVA) copolymers
EVA is  ideally  suited  for  preparation  of  molecular  diffusion  type 
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membranes because their permeability properties can be varied over a wide 
range by changing vinyl acetate content28, 29. The stiffness, tensile strength 
and softening point decrease with increasing vinyl acetate content, while the 
permeability and toughness increase. EVA has been shown to be chemically 
stable,  non-toxic and biocompatible.  A wide range of EVA polymers are 
commercially available with a range of vinyl acetate content (4 to 60%) 
Vinyl chloride polymers and copolymers 
Vinyl chloride polymers30 and copolymers useful for drug/ polymer 
matrix preparation include homo polymer vinyl chloride. CH2=CH-Cl and 
the  copolymer  having  a  high  vinyl  chloride  content.  PVC  needs 
plasticization  in  order  to  form  a  soft  and  flexible  film  suitable  for 
transdermal patch formulation. The commonly used plasticizers are dioctyl 
phthalate,  expoxidized  soya  bean  oil  & citric  acid  esters.  The  chemical 
nature,  the  proportion  of  the  plasticizers  and  the  drug  loading  in  the 
plasticized  polymer  matrix,  are  the  three  parameters  affecting  the  drug 
release and transport across the skin. 
Selection of drug candidates for transdermal delivery
The choice of drugs to be delivered is almost a difficult one, and 
careful  considerations  should  be  given  for  selection  of  suitable  drug 
molecule. The following are some of the desirable properties of a drug for 
transdermal delivery31, 32. 
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Physico – chemical properties of drug
• The drug should have a molecular weight of less than 7.50 
• The  drug  should  possess  balanced  lipophilic  hydrophilic 
characteristics  and  also  have  reasonable  solubility  in  both  lipid  and 
aqueous phases. The log P value should be in the range 1-3. 
• The melting point should be less than 200oC
• Saturated  aqueous  solutions  of  the  drug  should  have  pH  value 
between 5 and 9.
Biological properties of drug 
The biological half-life (t ½) should be less then 5-6 hours. 
• The drug should be potent with a daily systemic dose of less than 20 
mg. 
• The drug should not stimulate an immune reaction in the skin 
• The drug must not induce a cutaneous irritant or allergic response. 
Finally, in order to obtain the best  candidate for transdermal drug 
delivery, an attempt should be made to keep the melting point as low as 
possible.  Obviously, in some cases,  there will  be a compromise between 
optimizing both the partition and solubility parameters and incorporation of 
a suitable penetration enhancer31, 33, 34, 35.
Penetration enhancers
The success of transdermal drug delivery systems depends on the 
ability  of  the  drug  to  permeate  skin  in  sufficient  quantities  to  achieve 
required  therapeutic  plasma  levels.  Unfortunately  many  drugs  do  not 
possess, intrinsically, any great ability to cross the skin, and ways must be 
found to modify the barrier. This can be achieved chemically by the use of 
penetration enhancers36 or physically by iontophoresis37 and sonophoresis38.
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Chemical penetration enhancers 
The penetration enhancers are agents that increase the permeability 
of the skin39 or substances that temporarily reduce the impermeability of the 
skin40. The properties of an ideal penetration enhance are:
• Pharmacologically inert. 
• Non toxic, non irritating & non allergic 
• Rapid onset of action, predictable and suitable duration of action for 
drug used.
• Readily incorporated into the delivery system. 
• Following  removal  of  the  enhancer,  the  stratum  corneum  should 
immediately and fully recover its normal barrier property. 
• Chemically and physically compatible with the delivery system. 
• Commonly  used  chemical  enhancers  are  sulfoxides  and  Similar 
Compounds.
DimethylSulfoxide (DMSO)
DimethylSulfoxide (DMSO), the classic skin –permeation enhancer, 
is  a  powerful  aprotic  solvent.  DMSO  has  been  investigated  as  a  skin 
permeation enhancer for wide range of drugs including antibiotics steroids, 
narcotics and salicylates36. The activity of DMSO is highly concentration 
dependent with 60% and above generally required to produce a significant 
effect. 
Pyrrolidones
Pyrrolidones  provide more  activity  toward  hydrophilic  drugs  than 
lipophilic permeation. The permeation effect of pyrrolidones was reported 
to be concentration dependent. Unfortunately, despite the marked accelerant 
activity of the pyrrolidones for various drugs, the use of these agents may 
be constrained because they damage skin, especially at high concentrations. 
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Azone 
Azone  is  the  first  molecule  specifically  designed  as  a  skin 
penetration enhancer44. Chemically, it may be considered as a hybrid of a 
cyclic  amide as  in  the  pyrrolidones,  with an alkyl  sulfoxide.  It  has  low 
irritancy  and  it  active  at  low  concentrations  (typically  0.1  to  5%)  and 
permeation can further be enhanced with the use of a cosolvent such as 
propylene  glycol.  Azone  enhances  the  skin  transport  of  a  wide  variety 
including steroids and antibiotics45. 
Surfactants 
The  effect  of  surfactant  action  upon  the  skin  may  change  the 
physical state of water in the skin in such a way to permit greater freedom 
to the passage of charged, hydrophilic substances46.  These can accelerate 
and increase  transdermal  permeation  and percutaneous  absorption.  Their 
permeation promoting activity is due to the decrease in surface tension, to 
improve the wetting of the skin and to enhance the distribution of the drugs, 
among the three types of surface-active agents. Anionic laurate ions have 
the greatest penetration and strongest permeation promotion action47. 
The  following  surfactants  have  been  reported  as  penetration 
enhancers. Sodium lauryl sulfate, sodium diactyl –Sulfo Succinate, Sorbitan 
mono palmitate, lauryl ether etc. 
Miscellaneous enhancers 
In an attempt to reduce reversibility barrier function of the stratum 
corneum, which is the major obstacle administration of therapeutic agents, 
new  types  of  penetration  enhancers  like  naturally  occurring  cyclic 
terpenes48.  Few examples  used  as  penetration  enhancers  are  unsaturated 
cyclic ureas, cyclic monoterpenes, cineole, d- limonene etc, 
Physical means of penetration enhancers 
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Iontophoresis 
Trandermal iontophoresis deliver ions and charged molecules across 
the  skin  into  systemic  circulation  at  an  increased  rate  in  a  controllable 
manner by the use of electric current49. Although many drugs were studied 
as suitable agents for trandermal iontophoresis, peptide/protein (pp) drugs 
are best suited for this technique. Latest reports regarding use of reverse 
iontophoresis50 for monitoring the blood glucose is certainly going to steer 
and focus the research interests towards the development of commercially 
viable and acceptable formulations for PP drugs in general and for insulin in 
particular51. 
Sonophoresis 
The  effect  of  ultra  sound  on  transdermal  delivery  of  drugs  is 
reported52.  Ultra  sound  has  been  used  to  treat  a  wide  range  of  clinical 
conditions  and  to  transport  drugs  to  deeper  tissues  in  the  treatment  of 
inflammatory conditions. The movement of drugs through living intact skin 
and into soft tissue under the influence of an ultra sound perturbation is 
called  sonophoresis53.  The  technique  involves  placing  and  ultra  sound 
coupling agent on the skin over the area to be treated and messaging the 
area with an ultrasonic source.  An ultrasonic coupling agent is simply a 
cream gel or oil,  which maintains good contact between transducer head 
and skin. Recently sonophoresis has attracted lot of interest in transdermal 
delivery with the focus on peptide protein delivery.
Other excipients 
Adhesives 
The adhesive system used should be non irritating, non-sensitizing, 
should  be  compatible,  adhere  well  to  skin,  easy  to  remove  form  skin 
without  leaving  traces  of  adhesive,  should  not  affect  drug  permeation. 
Pressure –Sensitive Adhesives (PSA) have found application in transdermal 
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drug  delivery  because  of  the  need  to  intimate  contact  between  the 
trandermal  system and  the  skin  surface55.  The  adhesive  bond  formation 
involves a liquid like flow process resulting in adhesive wetting of the skin, 
surface upon application of pressure. When the pressure is removed, the 
adhesive sets in that state.  The PSA is a characteristic of a visco elastic 
material, significantly above its glass – transition temperature. Commonly 
employed  PSA  include  acrylate  copolymers,  polyisobutylenes  and 
polysiloxanes.  Acrylic  based  adhesives  are  less  irritating  than  silicone 
adhesives and the migration of ingredients into the adhesive during storage 
may also be less compared to other types. 
Backing layer 
The  backing  layer  must  be  impermeable  to  the  drugs  and  other 
components  of  the  device  and  also  it  should  be  impermeable  to  water 
vapour  i.e,  occlusive56.  The  most  commonly  used  backing materials  are 
polyester,  polyethylene-coextruded  films.  The  films  can  be  either  clear 
(Estraderm)  Flesh  coloured  (Catapres  –TTS)  or  metallized  (Transderm 
Scop). Other non-porous plastics with similar properties could equally well 
be used. If the entire area under the patch is active and the patch is not 
excessively large, then it is probably most convenient to use an occlusive 
backing if the patch has a central area containing the drug surrounded by a 
ring  adhesive  and  the  size  of  the  patch  is  relatively  large,  the  wearers 
comfort  may  be  increased  by  having  a  backing  material  that  is  non 
occlusive. 
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Peel strip
The  peel  Strip  prevents  drug  loss  when  it  has  irrigated  into  the 
adhesive  layer  on  storing  and  protects  the  finished  device  against 
contamination. The requirements for the peel strip are essentially the same 
as those for occlusive backing. The impermeable easily peelable films are 
made of polyester, foils etc57. 
Evaluation of transdermal drug delivery systems
Currently,  tremendous  research  is  going  on  in  the  evaluation  of 
T.D.D.S. The objective of this research is often to find correlation between 
laboratory results (In-vitro) and the transdermal absorption experienced by 
living subjects, so that in-vivo experimentation may be curtailed. There is 
no  elaborate  information  available  in  the  literature  on  the  in-vitro 
dissolution  methodology,  for  transdermal  patches.  The  various 
manufactures  of  transdermal  patches  (Novartis  Key  &  Searle)  employ 
different  dissolution  methods  from  the  standpoint  of  quality  assurance 
requirements.  There  is  a  definite  need  for  the  development  and 
implementation  of  a  single,  probably  universal,  dissolution  method  to 
assure  patch  –  to–  patch  uniform  release.  The  aim  of  in-vitro 
experimentation in TDD is to understand and/ or predict the delivery and 
penetration of a molecule form the skin surface into the body. Typically, this 
is  achieved  by  using  a  variety  of  skin  diffusion  cells  and  various 
experimental protocols. TDD can be described in three principal stages for 
understanding in designing of suitable in-vitro experiment58, 59, 60.
 Delivery of the molecules to the skin Surface 
 Passage of the molecule through the skin 
 Delivery of the molecule into the body in- vivo = recovery of the 
molecule in-vitro.
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HYPERLIPIDEMIAS AND STATIN THERAPY
Coronary  heart  disease61 (CHD) is  the  cause  of  about  half  of  all 
deaths  in  the  United  States.  The  incidence  of  CHD  is  correlated  with 
elevated  levels  of  low-density  lipoprotein  (LDL)  cholesterol  and 
triacylglycerols  and  with  low  levels  of  high-density  lipoprotein  (HDL) 
cholesterol.  Other  risk  factors  for  CHD  include  cigarette  smoking, 
hypertension, obesity, and diabetes. Cholesterol levels may be elevated as a 
result  of  an  individual's  lifestyle  (for  example,  by  lack  of  exercise  and 
consumption  of  a  diet  containing  excess  saturated  fatty  acids). 
Hyperlipidemias  can  also  result  from  a  single  inherited  gene  defect  in 
lipoprotein metabolism or,  more commonly, by a combination of genetic 
and lifestyle factors. Appropriate lifestyle changes in combination with drug 
therapy  can  lead  to  a  decline  in  the  progression  of  coronary  plaque, 
regression of pre-existing lesions, and reduction in mortality due to CHD by 
thirty to forty percent. Antihyperlipidemic drugs must be taken indefinitely; 
when  therapy  is  terminated,  plasma  lipid  levels  return  to  pretreatment 
levels. 
TREATMENT GOALS
Plasma  lipids  consist  mostly  of  lipoproteins-spherical 
macromolecular complexes of lipids and specific proteins (apolipoproteins). 
The  clinically  important  lipoproteins,  listed  in  decreasing  order  of 
atherogenicity,  are  LDL,  very-low-density  lipoprotein  (VLDL)  and 
chylomicrons, and HDL. The occurrence of CHD is positively associated 
with  high  total  cholesterol,  and  even  more  strongly  with  elevated  LDL 
cholesterol in the blood. In contrast to LDL, high levels of HDL cholesterol 
have been associated with a decreased risk of heart disease (figure 21.3). 
Reduction  of  the  LDL level  is  the  primary  goal  of  cholesterol-lowering 
therapy. Recommendations for the reduction of LDL cholesterol to specific 
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target levels are influenced by the coexistence of CHD and the number of 
other cardiac risk factors. The higher the overall risk of heart disease, the 
more aggressive the recommended LDL-lowering therapy.
A. Treatment options for hypercholesterolemia:
In patients with moderate hyperlipidemia, lifestyle changes, such as 
diet, exercise, and weight reduction, can lead to modest decreases in LDL 
and  increases  in  HDL levels.  However,  most  patients  are  unwilling  to 
modify their lifestyle sufficiently to achieve LDL treatment goals, and drug 
therapy may be required. Patients with LDL levels higher than 160mg/dL 
and  with  one  other  major  risk  factor  such  as  hypertension,  diabetes, 
smoking, or a family history of early CHD, are candidates for drug therapy. 
Patients  with  two  or  more  additional  risk  factors  should  be  treated 
aggressively,  with  the  aim  of  reducing  their  LDL  level  to  less  than 
130mg/dL.
B. Treatment options for hypertriacylglycerolemia:
Elevated  triacylglycerols  levels  are  independently  associated  with 
increased risk of CHD. Diet and exercise are the primary modes of treating 
hypertriacylglycerolemia. If indicated, niacin and fibric acid derivatives are 
the  most  efficacious  in  lowering  triacylglycerols  levels.  Triacylglycerol 
reduction is a secondary benefit of the statin drugs.
DRUGS THAT LOWER THE SERUM LIPOPROTEIN CONCENTRATION
Antihyperlipidemic drugs target the problem if elevated serum lipids 
with complementary strategies. Some of these agents decrease production 
of  the  lipoprotein  carriers  of  cholesterol  and  triacylglycerols,  whereas 
others  increase  the  degradation  of  lipoprotein.  Still  others  decrease 
cholesterol  absorption  or  directly  increase  cholesterol  removal  from the 
body. These drugs may be used singly or in combination. 
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HMG CoA reductase inhibitors:
3-Hydoxy-3-methylglutaryl (HMG) coenzyme A reductase inhibitors 
(commonly  known  as  statins)  lower  elevated  LDL  cholesterol  levels, 
resulting in a substantial reduction in coronary events and death from CHD. 
This  group  of  Antihyperlipidemic  agents  inhibits  the  first  committed 
enzymatic step of cholesterol synthesis. Therapeutic benefits include plaque 
stabilization,  improvement  of  coronary  endothelial  function,  inhibiton  of 
platelet thrombus formation, and anti-inflammatory activity. The value of 
lowering  the  level  of  cholesterol  with  statin  drugs  has  now  been 
demonstrated in 1) patients with CHD, with or without hyperlipidemia; 2) 
men with hyperlipidemia but no known CHD; and 3) men and women with 
average total and LDL cholesterol levels and no known CHD.
Mechanism of Action:
Inhibiton of HMG CoA reductase:
Lovastatin,  simvastatin,  pravastatin,  atorvastatin,  fluvastatin  and 
rosuvastatin are analogs of 3-hydroxy-3-methylglutarate,  the precursor of 
cholesterol. Lovastatin and simvastatin are lactones that are hydrolyzed to 
the active drug. Pravastatin and fluvastatin are active as such. Because of 
their strong affinity for the enzyme, all complete effectively to inhibit HMG 
CoA reductase, the rate limiting step in cholesterol synthesis. By inhibiting 
De  novo cholesterol  synthesis,  they  deplete  the  intracellular  supply  of 
cholesterol.  Potent  LDL cholesterol-lowering  statin  drugs,  followed  by 
pravastatin and fluvastatin and then lovastatin and simvastatin.
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Increase in LDL receptors:
Depletion of intracellular cholesterol causes the cell to increase the 
number of specific cell-surface LDL receptors that can bind and internalize 
circulating LDLs. Thus, the end result is a reduction in plasma cholesterol, 
both by lowered cholesterol synthesis and by increased catabolism of LDL. 
The  HMG  CoA  reductase  inhibitors,  like  the  bile  acid  sequesterant 
cholestyramine, can increase plasma HDL levels in some patients, resulting 
in an additional lowering of risk for CHD. Decreases in triacylglycerol also 
occur.
Therapeutic uses:
These drugs are effective in lowering plasma cholesterol levels in all 
types  of  cholesterol  levels  in  all  types  of  hyperlipidemias.  However, 
patients who are homozygous for familial hypercholesterolemia lack LDL 
receptors and, therefore, benefit much less from treatment with these drugs. 
It  should be noted that in spite of the protection afforded by cholesterol 
lowering,  about  one-fourth  of  the  patients  treated  with  these  drugs  still 
present  with  coronary  events.  Thus,  additional  strategies,  such  as  diet, 
exercise, or additional agents, may be warranted.
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DRUG PROFILE
ATORVASTATIN
OVERVIEW 62
Class 
This drug is a member of the following class (es): 
• Antihyperlipidemic 
• HMG-COA Reductase Inhibitor 
Synonyms 
• Atorvastatin
• Atorvastatin Calcium 
Physicochemical Properties 
Molecular Weight 
1209.42 (Prod Info Lipitor, 97) 
Solubility 
Atorvastatin  is  very  slightly  soluble  in  distilled  water,  pH  7.4-
phosphate buffer,  and acetonitrile,  slightly  soluble  in  ethanol,  and freely 
soluble in methanol. Atorvastatin is insoluble in aqueous solutions of pH 4 
and below. (Prod Info Lipitor(R), 2002) 
36
Storage and stability 
Store at controlled room temperature, 20 to 25 degrees Celsius (C) 
(68 to 77 degrees Fahrenheit (F)) (Prod Info Lipitor(R), 2004).
DOSING INFORMATION 
Adult 
a Diabetes  mellitus  type  2  -  Disorder  of  cardiovascular  system,  in 
patients  with  multiple  risk  factors  for  coronary  heart  disease; 
Prophylaxis  10  mg  ORALLY once  daily  (Prod  Info  Lipitor  (R), 
2005) 
b Disorder  of  cardiovascular  system,  in  patients  with  multiple  risk 
factors for coronary heart disease; Prophylaxis 10 mg ORALLY once 
daily 
c Familial hypercholesterolemia 
Homozygous  10  to  80  mg  ORALLY  once  daily  (Prod  Info 
LIPITOR(R) tablets, 2005) 
d Familial type 3 hyperlipoproteinemia 
10 to 80 mg ORALLY once daily; evaluate lipid levels after 2 to 4 
wk and adjust doses accordingly 
e Hypercholesterolemia,  primary  (heterozygous  familial  and  non-
familial)  and  mixed  dyslipidemia  (Fredrickson  types  IIa  and  IIb) 
initial, 10 to 20 mg ORALLY once daily; dosage range is 10 to 80 
mg once daily; evaluate lipid levels after 2 to 4 wk and adjust doses 
accordingly (Prod Info LIPITOR(R) tablets, 2005) 
f Hypertriglyceridemia 
10 to 80 mg ORALLY once daily; evaluate lipid levels after 2 to 4 
wk and adjust doses accordingly 
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Pediatric 
a Familial hypercholesterolemia 
Heterozygous, with LDL-C 160 or 190 mg/dL or more AND positive 
family  history or  2 or  more cardiovascular  disease  risk factors  in 
boys and postmenarchal girls 10 to 17 yr, initially 10 mg ORALLY 
daily; titrate at 4-wk intervals up to MAX 20 mg ORALLY daily 
(Prod Info LIPITOR(R) tablets, 2005) 
b Familial hypercholesterolemia - homozygous 
10 to 80 mg ORALLY once daily (Prod Info LIPITOR(R) tablets, 
2005) 
Contraindications 
• Hypersensitivity to atorvastatin 
• Liver disease 
• Pregnancy or lactation 
• Unexplained, persistent elevation of serum transaminases
Serious adverse effects 
• Rhabdomyolysis 
Clinical Applications 
 FDA approved indications 
a Diabetes  mellitus  type  2  -  Disorder  of  cardiovascular  system,  in 
patients  with  multiple  risk  factors  for  coronary  heart  disease; 
Prophylaxis 
b Disorder  of  cardiovascular  system,  in  patients  with  multiple  risk 
factors for coronary heart disease; Prophylaxis 
c Familial hypercholesterolemia - heterozygous, with LDL-C 160 or 
190  mg/dL or  more  AND  positive  family  history  or  2  or  more 
cardiovascular disease risk factors 
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d Familial hypercholesterolemia - homozygous 
e Familial type 3 hyperlipoproteinemia 
f Hypercholesterolemia,  primary  (heterozygous  familial  and  non-
familial) and mixed dyslipidemia (Fredrickson types IIa and IIb) 
g Hypertriglyceridemia 
ADME 
ABSORPTION 
A) Bioavailability 
 14% (oral route) (Lennernas, 2003). 
a Absolute  bioavailability  was  14%  after  a  10-mg  oral  dose 
(Lennernas, 2003). 
b Atorvastatin  is  rapidly  absorbed  after  oral  administration  in  the 
fasting state (Prod Info Lipitor(R), 2003; Gibson et al, 1996). 
B) Effects of Food 
1) rate of absorption slowed (Lennernas, 2003). 
DISTRIBUTION 
A) Distribution Sites 
Protein Binding 
98% or more (Lennernas, 2003; Prod Info Lipitor(R), 2003) 
B) Distribution Kinetics 
Volume of Distribution 
381 liters(Lennernas, 2003). 
Following  a  5-milligram  intravenous  infusion,  the 
volume of distribution was 381 liters (Lennernas, 2003). 
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Metabolism 
A) Metabolism sites and kinetics 
1) LIVER, significant (Lennernas, 2003). 
a Hepatic cytochrome P450 3A4 is the major metabolic pathway of 
atorvastatin (Lennernas, 2003). 
b Atorvastatin  is  a  candidate  for  drug-drug  interactions  when  co- 
administered with potent CYP3A4 inhibitors, such as itraconazole, 
erythromycin, and grapefruit juice. Glucuronidation is another step 
in the metabolism of atorvastatin and its metabolites, and gemfibrozil 
is  thought  to  inhibit  glucuronidation  of  atorvastatin  (Lennernas, 
2003). 
EXCRETION 
A) Kidney 
Renal Excretion (%)- 1 to 2 
B) Other 
BILE 
Atorvastatin and its metabolites are eliminated mostly in the bile; the 
biliary  route  is  the  major  route  of  elimination  of  atorvastatin  and  its 
metabolites (Lennernas, 2003; Prod Info Lipitor(R), 2003). 
Elimination Half-life 
A) Parent compound 
• 7 to 14 hours (Lennernas, 2003; Prod Info Lipitor(R), 2003; Gibson 
et al, 1996). 
o Half-life is longer in elderly (19 hours) than in young subjects 
(Gibson et al, 1996). 
o Average half-life was 11.5 and 11.8 hours, respectively, after 
single and multiple dosing of atorvastatin 40 milligrams in a 
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study of 23 patients on hemodialysis.  Average half-life was 
10.9 and 14.7 hours,  respectively,  after single  and multiple 
dosing of atorvastatin 80 milligrams in the same study. There 
was high inter-subject variability (Lins et al, 2003). 
B) Metabolites 
9 to 32 hours (Lins et al, 2003) 
a After a single dose of 40 milligrams (mg) atorvastatin, the half-life 
of o-OH- atorvastatin ranged between 8.7 and 10.8 hours in healthy 
volunteers.  The  half-life  was  23.6  and  32.1  hours  after  multiple 
dosing of 40 mg and 80 mg, respectively, in healthy volunteers (Lins 
et al, 2003). 
b The half-life of o-OH-atorvastatin 18 and 22.3 hours after single and 
multiple  dosing  of  atorvastatin  40  milligrams  in  a  study  of  23 
patients on hemodialysis. Average half-life was 17.7 and 19 hours, 
respectively,  after  single  and  multiple  dosing  of  atorvastatin  80 
milligrams in the same study. There was high inter-subject variability 
(Lins et al, 2003). 
CAUTIONS
Contraindications 
• Hypersensitivity to atorvastatin 
• Liver disease 
• Pregnancy or lactation 
• Unexplained, persistent elevation of serum transaminases 
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Precautions 
a Concomitant  therapy  with  fibrates,  niacin,  cyclosporine, 
erythromycin,  or  azole  antifungals  may  increase  the  risk  of 
myopathy 
b Heavy alcohol use 
c History of liver disease 
d Reduce doses or discontinue therapy if serum transaminase levels 3 
times the upper limit of normal persist 
e Withhold  temporarily  or  discontinue  therapy  in  any  patient  who 
develops a condition suggestive of or predisposing to myopathy or 
renal failure
POLYMER PROFILE
EUDRAGIT RS100:
• Ammonio Methacrylate Copolymer, Type A“ Ph. Eur.
• Ammonio Methacrylate Copolymer, Type A " USP/NF
• Aminoalkylmethacrylate Copolymer RS" JPE
Chemical structure
EUDRAGIT® RS 100 is copolymer of acrylic and methacrylic acid 
esters with a low content in quaternary ammonium groups. The ammonium 
groups are present as salts and make the polymers permeable.
The average molecular weight is approx. 150,000.
Characteristics
Description
EUDRAGIT® RS 100: colourless, clear to cloudy granules with a 
faint amine-like odour.
Solubility
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1 g of the substances dissolves in 7 g aqueous methanol, ethanol and 
isopropyl alcohol (containing approx. 3 % water),  as well  as in acetone, 
ethyl acetate and methylene chloride to give clear to cloudy solutions. The 
substances  are  practically  insoluble  in  petroleum  ether,  1  N  sodium 
hydroxide and water.
Tests
Test solution
A 12.5 % solution of the dry substance is used for the test solution: a 
quantity  of  the  substance  of  corresponding  to  12.5  g  dry  substance  is 
dissolved in a mixture of 60 % (w/w) isopropyl alcohol and 40 % (w/w) 
acetone.
Particle size
EUDRAGIT® RS: at least 90 % < 0.315 mm according to Ph. Eur. 
2.1.4 or USP <811>.
Film formation
When the Test solution is poured onto a glass plate a clear film forms 
upon evaporation of the solvents.
Viscosity / Apparent viscosity
Max. 15 mPa. s. The viscosity of the Test solution is determined by 
means of a Brookfield viscometer (UL adapter / 30 rpm / 20 °C).
Refractive index
nD 20: 1.380 - 1.385. The refractive index of the Test solution is 
determined according to Ph. Eur. 2.2.6.
Relative density
d20 20 : 0.816 - 0.836. The relative density of the Test solution is 
determined according to Ph. Eur. 2.2.5.
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Monomers
Max. 100 ppm ethyl acrylate and max. 50 ppm methyl methacrylate 
according to the Ph. Eur. or USP/NF monograph.
IDENTITY TESTING
First identification
The material must comply with the tests for "Assay" and "Viscosity / 
Apparent viscosity."
Second identification
IR spectroscopy on a dry film approx. 15 m thick. To obtain the  
film, a few drops of the Test solution are placed on a crystal disc (KBr, 
NaCl) and dried in vacuo for about 2 hours at 70 °C. The figures on page 4 
show the characteristic bands of the ester groups at 1,150 - 1,190 and 1,240 
-  1,270  cm-1,  as  well  as  the  C  =  O  ester  vibration  at  1,730  cm-1.  In 
addition, CHX vibrations can be discerned at 1,385, 1,450, 1,475 and 2,950 
- 3,000 cm-1.
Detection in dosage forms
The  dosage  forms  are  extracted  using  the  solvents  listed  under 
"Solubility," if necessary after crushing. Insoluble substances are isolated 
by  filtration  or  centrifugation.  The  clear  filtrate  is  boiled  down and the 
residue identified by IR spectroscopy.
Storage
• Protect from warm temperatures (USP, General Notices).
• Protect from moisture.
EUDRAGIT® RS 100 tend to form lumps at warm temperatures. 
This has no influence on the quality. The lumps are easily broken up again.
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Incompatibilities 
Incompatibilities  occur  with  certain  polymethacrylate  dispersions 
depending  upon  the  ionic  and  physical  properties  of  the  polymer  and 
solvent.  For  example,  soluble  electrolytes,  pH  changes,  some  organic 
solvents, and extremes of temperature may cause coagulation; for example, 
dispersions  of  Eudragit  L 30  D,  RL 30D,  L 100-55  and  Rs  30  D  are 
incompatible with magnesium stearate. Eastacryl 30D, Kollicoat MAE 30D, 
and Kollicoat MAE 30 DP are also incompatible with magnesium state.
Interactions between polymethacrylates and some drugs can occur, 
although solid polymethacrylates and organic solutions are generally more 
compatible than aqueous dispersions.
Safety 
Polymethacrylate  copolymers  are  widely  usd  as  film-  coating 
materials in oral pharmaceutical formulations. They are also used in topical 
formulations  and  are  generally  regarded  as  nontoxic  and  nonirritant 
materials.
A daily intake of 2 mg/kg body-weight of Eudragit (equivalent to 
approximately 150 mg for an average adult) may be regarded as essentially 
safe in humans.
Handling precautions 
Observe  normal  precautions  appropriate  to  the  circumstances 
and  quantity  of  material  handled.  Additional  measures  should  be  tkane 
when  handling  organic  solutions  of  polymethacrylates.  Eye  protection, 
gloves, and a dust mask or respirator are recommended. Polymethacrylates 
should be handled in well-ventilated environment and measures should be 
taken to prevent dust formation63. 
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HYPROMELLOSE 
Nonproprietary Names 
BP: Hypromellose 
JP: Hydroxypropylmethylcellulose 
PhEur: Hypromellosum
USP: Hypromellose
Synonyms 
Benecel MHPC; hydroxypropyl methyl ether; E464; hydroxypropyl 
methylcellulose; HPMC; Methocel; methylcellulose propylene glycol ether; 
merthyl  hydroxypropylcellulose;  Metolose  ;  Pharmacoat  ;  Spectracel  6  ; 
Spectracel 15; Tylopur.
Chemical Name and CAS registry number 
Cellulose, 2-hydroxypropyl-methyl ether [9004-65-3]
Empirical formula molecular weight 
The PhEur 2002 describes hypromellose as a partly O-methylated 
and O-(2-hydroxypropylated) cellulose. It is available in several grades that 
vary in viscosity and extent of substitution. Grades may be distinguished by 
appending a number indicative of the apparent viscosity, in mPa s, of a 2% 
w/w  aqueous  solution  at  20°C.  Hypromellose  defined  in  the  USP  25 
specifies  the  substitution  type  by  appending  a  four-digit  number  to  the 
nonproprietary name: e.g., hypromellose 1828. The first two digits refer to 
the  approximate  percentage content  of  the  methoxy group (OCH3).  The 
second  two  digits  refer  to  the  approximate  percentage  content  of  the 
methoxy group (OCH3). The second two digits refer to the approximate 
percentage content of the hydroxypropoxy group (OCH2CH (OH) CH3), 
calculated on a dried basis. Molecular weight is approximately 10 000-1 
500  000.  The  Jp  2001  includes  three  separate  monographs  for 
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hypromellose:  hydroxypropylmethylcellulose  2208,  2906,  and  2910, 
respectively. 
Functional category 
Coating agent; film-former; rate – controlling polymer for sustained 
release;  stabilizing  agent;  suspending  agent;  tablet  binder;  viscosity  – 
increasing agent. 
Applications in pharmaceutical formulation or technology 
Hypromellose  is  widely  used  in  oral  and topical  pharmaceutions, 
Particularly  ophthalmic  preparations.  Compared  with  methylcellulose, 
hypromellose produces solutions of greater clarity, with fewer undispersed 
fibers present, and is therefore preferred in formulations for ophthalmic use. 
Hypromellose at concentrations between 0.45-1.0% w/w may be added as a 
thickening agent to vehicles for eye drops and artificial tear solutions. 
Hypromellose is also used as an emulsifier, suspending agent, and 
stabilizing agent in topical gels and ointments. As a protective colloid, it 
can prevent droplets and particles from coalescing or agglomerating, thus 
inhibiting the formation of sediments.
In addition, hypromellose is used in the manufacture of capsules, as 
an adhesive in plastic bandages, and as a wetting agent for hard contact 
lenses. It is also widely used in cosmetics and food products.
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Description
Hypromellose is an odorless and tasteless,  white or creamy white 
fibrous or granular powder.
Pharmacopeial specifications 
Typical Properties
Acidity / alkalinity: pH = 5.5 – 8.0 for a 1% w/w aqueous solution
Ash: 1.5-3.0% depending upon the grade
Autoignition temperature: 360°C   
Density (tapped): 0.557 g/cm3
Density (tapped): 1.326 g/cm3  
Melting point: browns at 190-200°C; chars at 225-230°C.
Glass transition temperature is 170-180°C.
Moisture content:  hypromellose  absorbs  moisture  from the atmosphere, 
the  amount  of  water  absorbed  depending  and  relative  humidity  of  the 
surrounding air. 
Solubility:  soluble  in  cold  water,  forming  a  viscous  colloidal  solution; 
practically insoluble in chloroform, ethanol (95%), and ether, but soluble in 
mixtures  of  ethanol  and  dichloromethane,  mixtures  of  methanol  and 
dichloromethane,  and  mixtures  of  water  and  alcohol.  Certain  grades  of 
hypromellose  are  soluble  in  aqueous  acetone  solutions,  mixtures  of 
dichloromethane and propan-2-ol, and other organic solvents. 
Specific gravity: 1.26
Viscosity  (dynamic):  Wide  ranges  of  viscosity  types  are  commercially 
available.  Aqueous  solutions  are  most  commonly  prepared,  although 
hypromellose may also be dissolved in aqueous alcohols such as ethanol 
and  propan-2-ol  provided  the  alcohol  content  is  less  than  50%  w/w. 
Dichloromethane and ethanol mixtures may also be used to prepare viscous 
hypromellose solutions. Solutions prepared using organic solvents tend to 
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be  more  viscous;  increasing  concentration  also  produces  more  viscous 
solutions; 
Methocel grade Nominal Viscosity (MPa s)
K 100LVP 100 80-120
K4M 4000 3000-5600
K15MP 15000 12000-2100
K100MP 100 000 80 000-120 000
To  prepare  an  aqueous  solution,  it  is  recommended  that 
hypromellose is dispersed and thoroughly hydrated in about 20-30% of the 
required  amount  of  water.  The  water  should  be  vigorously  stirred  and 
heated  to  80-90°C,  then  the  remaining  hypromellose  added.  Cold  water 
should then be added to produce the required volume.
When a water – miscible organic solvent such as ethanol, glycol, or 
mixtures of ethanol and dichloromethane is used, the hypromellose should 
first be dispersed into the organic solvent, at a ratio of 5-8 parts of solvent 
to part of hypromellose. Cold water is then added to produce the required 
volume. 
Stability and storage conditions
Hypromellose powder is a stable material, although it is hygroscopic 
after drying.
Solutions are stable at pH 3-11. Increasing temperature reduces the 
viscosity  of  solutions.  Hypromellose  undergoes  a  reversible  sol-gel 
transformation upon heating and cooling, respectively. The gel point is 80-
90°C, depending upon the grade and concentration of material.
Aqueous  solutions  are  comparatively  enzyme-resistant,  providing 
good  viscosity  stability  during  long-term  storage.However,  aqueous 
solutions are liable to microbial spoilage and should be preserved with an 
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antimicrobial  preservative:  when hypromellose  is  used  as   a  viscosity  – 
increasing  agent  in  ophthalmic  solutions,  benzalkonium  chloride  is 
commonly  used  as  the  preservative.  Aqueous  solutions  may  also  be 
sterilized by autoclaving; the coagulated polymer must be redispersed on 
cooling by shaking.
Hypromellose powder should be stored in a well-closed container, in 
a cool, dry place.
Incompatibilities
Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic,  hypromellose  will  not  complex  with  metallic  salts  or  ionic 
organics to form insoluble precipitates.
safety 
Hypromellose  is  widely  used  as  an  excipient  in  oral  and  topical 
pharmaceutical formulations. It is also used extensively in cosmetics and 
food products. 
Hypromellose  is  generally  regarded as  a  nontoxic  and nonirritant 
material, although excessive oral consumption may have a laxative effect. 
The WHO has not specified an acceptable daily intake fro hypromellose 
since the  levels  consumed were  not  considered to  represent  a  hazard  to 
health. 
LD 50 (mouse, IP): 5 g/kg (16)
LD 50 (rat, IP): 5.2 g/kg
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Handling precautions 
Observe  normal  precautions  appropriate  to  the  circumstances  and 
quantity of material handled. Hypromellose dust may be irritant to the eyes 
and eye protection is recommended. Excessive dust generation should be 
avoided to minimize the risks of explosion. Hypromellose is combustible63. 
ETHYLCELLULOSE 
Nonproprietary Names 
BP:  Ethylcellulose 
PhEur: Ethylcellulosum 
USPNF: Ethylcellulose
Synonyms 
Aquacoat ECD; Aqualon; E462; Ethocel; Surelease.
Chemical Name and CAS registry number  
Cellulose ethyl ether [9004-57-3]
Empirical formula & molecular weight 
Ethylcellulose  with  complete  substitution  (DS=3)  is  C12H23O6 
(C12H22O5)n  C12H23O5 where  n  can  vary  to  provide  a  wide  variety  of 
molecular weights. Ethylcellulose, and ethyl ether of cellulose, is a long-
chain  polymer  of  β–  anhydroglucose  units  jointed  together  by  acetal 
linkages.   
Functional category 
Coating agent; flavoring fixative; tablet binder; tablet filler; viscosity 
– increasing 
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Applications in pharmaceutical formulation or technology  
Ethylcellulose  is  widely  used  in  oral  and  topical  pharmaceutical 
formulations; see Table A.
The  main  use  of  ethylcellulose  in  oral  formulations  is  as  a 
hyudrophobic  coating  agent  for  tablets  and  granules.  Ethylcellulose 
coatings are used to modify the release to a drug  to mask an unpleasant 
taste,  or  to  improve  the  stability  of  a  fomualtion;  for  example,  where 
granules  are  coated  with  ethylcellulose  to  inhibit  oxidation.  Modified  – 
release tablet formulations may also be produced using ethylcellulose as a 
matrix former.
Ethylcellulose, dissolved in an organic solvent or solvent mixture, 
can  be  used  on  its  own  to  produce  water  –  insoluble  films.  Higher  – 
viscosity ethylcellulose grades tend to produce stronger and more durable 
films. Ethylcellulose films may be modified to alter their solubility  by the 
addition of hypromellose or a plasticize. An aqueous polymer dispersion (or 
latex)  of  ethylcellulose  such  as  Aquacoat  ECD  (FMC  Biopolymer)  or 
Surelease  (Colorcon)  may  also  be  used  to  produce  ethylcellulose  films 
without the need for organic solvents.
Drug release through ethylcellulose – coated dosage forms can be 
controlled by diffusion through the film coating. This can be a slow process 
unless a large surface area (e.g.pellets or granules compared with tablets) is 
utilized. In those instances, aqueous ethylcellulose dispersions are generally 
used to coat granules or pellets. Ethylcellulose-coated beads and granules 
have also demonstrated the ability to absorb pressure and hence protect the 
coating from fracture during compression. 
High-viscosity  grades  of  ethylcellulose  are  used  in  drug 
microencapsulation.
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Release of a drug from an ethylcellulose microcapsule is a function 
of the microcapsule wall thickness and surface area.
In tablet formulations, ethylcellulose may additionally be employed 
as a binder; the ethylcellulose may additionally be wet-granulated with a 
solvent such as ethanol (95%). Ethylcellulose produces hard tablets with 
low friability, although they may demonstrate poor dissolution.
Ethylcellulose  has  also  been  used  as  an  agent  for  delivering 
therapeutic agents from oral (e.g., dental) appliances.
In topical formulations, Ethylcellulose is used as a thickening agent 
in creams, lotions, or gels, provided an appropriate solvent is used.
Ethylcellulose is additionally used in cosmetics and food products.
Table: A- Uses of Ethylcellulose
Use Concentration (%)
Microencapsulation 10.0-20.0
Sustained – release tablet coating 3.0-20.0
Tablet coating 1.0-3.0
Tablet granulation 1.0-30.0
Description
Ethylcellulose is a tasteless, free- flowing, white or light tan-colored 
powder.
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Typical properties 
Density (bulk): 0.4g/cm 3 
Glass transition temperature: 129-133°C
Moisture content: 
Ethylcellulose  absorbs  very  little  water  from humid air  or  during 
immersion, and that small amount evaporates readily. 
Solubility
Ethylcellulose is practically insoluble in glycerin, propylene glycol, 
and water. Ethylcellulose that contains less than 46.5% of ethoxyl groups is 
freely soluble in chloroform, methyl acetate,  and tetrahydrofuran, and in 
mixtures of aromatic hydrocarbons with ethanol (95%). Ethylcellulose that 
contains not less than 46.5% of ethoxyl acetate, methanol, and toluene.
Specific gravity: 1.12-1.15 g/cm3
Viscosity 
The viscosity of ethylcellulose is measured typically at 25 C using 
5% w/v ethylcellulose dissolved in a solvent blend of 80% toluene: 20% 
ethanol  (w/w).  Grades  of  ethylcellulose  with  various  viscosities  are 
commercially available; see Table III. They may be used to produce 5% w/v 
solutions in organic solvent blends with viscosities nominally ranging from 
7  to  100  mPas  (7-100  cp).  Specific  ethylcellulose  grades,  or  blends  of 
different  grades,  may be used to  obtain solutions  of  a desired viscosity. 
Solutions of higher viscosity tend to be composed of longer polymer chains 
and produce strong and durable films.
The viscosity of an ethylcellulose solution increase with an increase 
in ethylcellulose concentration; e.g., the viscosity of a 5% w/v solution of 
Ethocel Standard 4 Premium is 4mPas (4cP) and of a 25% w/v solution of 
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the same ethylcellulose grade is 850 mPas (850cP). Solutions with a lower 
viscosity may be obtained by incorporating a higher percentage (30-40%) 
of  a  low  molecular  –weight  aliphatic  alcohol  such  as  ethanol,  butanol, 
propan -2-ol,  or  n-butanol  with toluene.  The viscosity  of  such solutions 
depends  almost  entirely  on  the  alcohol  content  and  is  independent  of 
toluene.            
In addition, nonpharmaceutical grades of ethylcellulose that differ in 
their ethoxyl content and degree of polymerization are available.
Stability and storage conditions
Ethylcellulose  is  a  stable,  slightly  hygroscopic  material.  It  is 
chemically  resistant  to  alkalis,  both  dilute  and concentrated,  and to  salt 
solutions, although it is more sensitive to acidic materials than are cellulose 
esters.
Ethylcellulose is subject to oxidative degradation in the presence of 
sunlight or UV light at elevated temperatures. This may be prevented by the 
use of antioxidant and chemical additives that absorb light in the 230-340 
nm range. 
Ethylcellulose should be stored at a temperature not exceeding 32°C 
(90°F) in a dry area away from all sources of heat. It should not be stored 
next to peroxides or other oxidizing agents. 
Incompatibilities
Incompatible with paraffin wax and microcrystalline wax.
Safety 
Ethylcellulose  is  widely  used  in  oral  and  topical  pharmaceutical 
formulations.  It  is  also  used  in  food  products.  Ethylcellulose  is  not 
metabolized  following  oral  consumption  and  is  therefore  a  noncalorific 
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substance. Because ethycellulose is not metabolized it is not recommended 
for pareteral products; paranteral use may be harmful to the kidneys.
Ethylcellulose is generally regarded to be a health hazard; the WHO 
has not specified an acceptable daily intake.
LD50 (rabbit, skin): >5 g/kg (28)
LD50 (rat,oral): >5 g/kg
Handling precautions 
It  is  important  to  prevent  fine  dust  clouds  of  ethylcellulose  from 
reaching  potentially  explosive  levels  in  the  air.  Ethylcellulose  is 
combustible. Ethylcellulose powder may be an irritant to the eyes and eye 
protection should be worn63.
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REVIEW OF LITERATURE
Nagaraj64 et.al.,(2007) developed  simultaneous  Quantitative 
resolution  of  Atorvastin  calcium  and  Fenofibrate  in  pharmaceutical 
preparation by using derivative ratio spectrophotometry  and chemometric 
Calibrations. The calibration was constructed by using the absorption data 
matrix corresponding to the concentration data matrix, with measurements 
in  the  range  of  231-310nm  (∆ λ=1nm)  I  their  zero-order  spectra.  The 
Linearity range was found to be 4-22 and 2-20 mg/ml for Atorvastatin and 
Fenofibrate, respectively.
Udhumansha  Ubaidulla65 et.al.,(2007) have  developed  the 
carvedilol  transdermal  patches  which have great  utility  and are  a  viable 
option  for  effective  and  controlled  management  of  hypertension.  It  was 
developed with different ratios of hydrophilic and hydrophobic polymeric 
combinations by the solvent evaporation techniques. The results followed 
Higuchi  Kinetics (r=0.9953- 0.9979),  and the mechanism of release was 
diffusion mediated. As a result, patches with Eudragit RL: Eudragit RS (at 
8:2)  and Ethyl  cellulose:  polyvinylpyrrolidone.  (at  7.5:2.5)  combinations 
were chosen for further in vivo studies. The antihypertensive activity of the 
patches  in  comparison  with  that  of  oral  carvedilol  was  studied  using 
methylprednisolone acetate- induced hypertensive rats. It was observed that 
both the patches significantly controlled hypertension from the first hour 
with improved bioavailability of 62% and 71% respectively. The developed 
transdermal patches increase the efficacy of carvedilol for the therapy of 
hypertension.
Tanwar  Y.S66 et.al.,(2007) developed  transdermal  patches  of 
carvedilol  with  a  HPMC-  drug  reservoir  by  the  solvent  evaporation 
technique.  In  this  investigation,  the  membranes  of  Eudragit  RL100  and 
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Eudragit RS100 were cast to achieve controlled release of the drug. The 
prepared  patches  possessed  satisfactory  physicochemical  characteristics. 
Thickness,  mass  and  drug  content  were  uniform  in  prepared  patches. 
Moisture  vapour  transmission  through  the  patches  followed  zero-order 
kinetics. In vitro permeation studies were performed using K-C diffusion 
cell across hairless guinea pig skin and followed the super case II transport  
mechanism. The effects of non-ionic surfactants Tween 80 and span 80 on 
drug  permeation  were  studied.  The  non-ionic  surfactants  in  the  patches 
increased  the  permeation  rate,  span  80  exhibiting  better  enhancement 
relative  to  Tween  80.  The  patches  were  seemingly  free  of  potentially 
hazardous skin irritation.
Reddy  M.S. 67 et.al.,(2006) developed  transdermal  patches  of 
metoclopramide  hydrochloride  using  polyvinyl  alcohol  and  polyvinyl 
pyrrolidone for the treatment of vomiting and nausea. The physicochemical 
parameters like thickness, drug content, weight variation, moisture content, 
moisture uptake and drug permeation studies (through dialysis sac and rat 
skin) were evaluated for the prepared patches. The formulations exhibited 
uniform thickness and weight, good drug content and little moisture content 
and  uptake.  In  the  in  vitro  drug  permeation  studies,  the  formulations 
showed burst release of the drug in initial hours and thereafter drug was 
released slowly up to 12 hrs. The drug release mechanism from the patches 
was found to be diffusion dominated. The stability studies indicated that all 
patches  maintained  good  physical  appearance  and  drug  content  for  6 
months at 40° / 75% RH.  
Patel Parul68 et.al.,(2006) prepared monolithic transdermal films of 
repaglinide  using  Eudragit  NE 30D,  Acrycoat  RL100,  Cellulose  acetate, 
Polyvinyl Pyrrolidone, Ethylcellulose (individual and combination). Those 
prepared films were evaluated for weight variation, thickness uniformity, 
58
tensile strength, content uniformity and invitro permeation study. The order 
of permeation of the drug from different polymeric films Eudragit NE30D > 
Ethylcellulose:  Polyvinyl  Pyrrolidone  >  Cellulose  acetate:  PVP> 
Ethylcellulose > Eudragit RL100: PVP > cellulose acetate > Acrycoat: PVP. 
The  drug release  mechanism from all  monolithic  systems was  diffusion 
controlled and followed zero order kinetics.
Rathore  RPS69 et.al.,(2006) fabricated  matrix  type  transdermal 
patches  of  Terbutaline  sulphate  using  polymers  like  ethylcellulose  (EC), 
Povidone (PVP) and cellulose acetate (CA). The formulated patches were 
found to be physically stable with regard to drug content, tensile strength, 
folding endurance, thickness and weight variation. Formulations CP3 (CA: 
PVP at 3:2) and EP2 (EC: PVP at 2:3) were found to be best suitable and 
found to follow diffusion controlled permeation.
Saraf Swarnlata70 et.al., developed both reservoir as well as matrix 
transdermal  delivery  system  of  timolol  maleate  using  polymers  like 
hydroxypropyl methyl cellulose, Ethylcellulose, and polyvinyl alcohol. Out 
of all the formulations PVA10 (i.e. PVA 10% w/v) and HE2 (HPMC: EC: : 
2:8)  were  found  to  be  physically  stable  regarding  drug  content,  tensile 
strength, toughness and water vapour transmission rate. Both the patches 
follows  diffusion  controlled  drug  permeation  and  high  permeation  with 
PVA10 while reservoir system follows zero order permeation kinetics.
Rajagopal k. 71 et.al.,(2005) formulated the matrix type transderamal 
patches of Nimesulide using different polymers; like HPMC, EC, and MC; 
alone or in combination ; dibutyl phthalate as the plasticizer and aluminum 
foil  as  the  backing  membrane.  In-vitro  release  studies  of  the  prepared 
formulations  were  performed  by  K-C  diffusion  cell  through  cellophane 
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membrane in phosphate buffer solution (pH 7.4). After all the evaluations, 
the  studies  showed that  Hydroxy Propyl  Methyl  Cellulose  (HPMC) and 
Ethyl  Celluose  (EC)  Combination  (2:2)  might  be  the  suitable  polymer 
combination  for  development  of  transdermal  drug  delivery  system  of 
Nimesulide.
Biswajit  Mukherjee72 et.al.,(2005) developed  a  matrix  type 
transdermal drug delivery system of Dexamethasone using blends of two 
different polymeric combinations, Povidone(PVP) with ethyl cellulose(EC) 
and  Eudragit  with  PVP.  Physical  studies  including  moisture  content, 
moisture uptake, flatness to study the stability of the formulation. In vitro 
dissolution and diffusion studies were performed to study the drug content 
and diffusion profile of the patches, respectively. The formulations of PVP: 
EC  (1:5)  was  found  to  provide  slowest  release  of  drug.  Hence  it  was 
concluded that  PVP- EC polymers  are  better  suited than PVP- Eudragit 
polymers for the development of TDDS of Dexamethasone.
Ubaidulla73 et.al.,(2004) aimed  at  improving  the  permeability  of 
Carvedilol from transdermal films, which is made by using hydroxy propyl 
methyl  cellulose  (HPMC)  as  polymeric  matrix  and  propylene  glycol  as 
plasticizer. Sodium lauryl Sulphate (SLS), Tween 20, Dimethyl Sulfoxide 
(DMSO)  and  propylene  glycol  (PEG  400)  were  used  as  permeation 
enhancers.  It  was  found  that  the  permeation  enhancers  increased  the 
permeation  of  carvedilol  in  the  order  as:  Tween 20> SLS> PEG 400 > 
DMSO. The effect of iontophoresis on permeation of carvedilol transdermal 
films  were  studied  alone  and  mixed  with  enhancers.  The  data  clearly 
showed  that  permeation  enhancers  and  iontophoresis  synergistically 
enhanced permeability of carvedilol from its films. The results suggested 
that the combination of permeation enhancers and iontophoresis could be 
useful  for  increasing  in  the  skin  permeability  of  carvedilol  through  the 
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matrix TDDS. 
Kusum Devi74 et.al.,(2003) designed and evaluated matrix diffusion 
controlled  transdermal  patches  of  verapamil  hydrochloride  using  four 
different polymers (individual and combination): Eudragit RL100, Eudragit 
RS100, hydroxyl propyl methyl cellulose 15 cps, and ethyl cellulose. The 
effect of the polymers on the technological properties, i.e., drug releases, 
water  vapour  transmission  rate  (WVTR)  and  percentage  moisture  loss 
(ML),  Percentage  moisture  absorption  (MA),  folding  endurance,  and 
thickness  were  evaluated.  The  patch  containing  ERL 100 alone  showed 
maximum WVTR, % MA, and % ML, which could be attributed  to  its 
hydrophilic nature. As expected, substitution with ER100, HPMC, and EC 
decreased all the above values in accordance with their decreasing degree of 
hydrophilicity.  Among  the  eight  formulations,  Eudragit  RL100:  HPMC 
(8:2) combination emerged as the most satisfactory formulation insofar as 
its  technological  properties  were  concerned  out  in  rabbits.  The 
pharmacokinetic  parameters  calculated  from  blood  levels  of  the  drug 
revealed a profile typical of a sustained release formulation.
Biswajit  Mukherjee75 et.al.,(2003) aimed  at  selecting  a  suitable 
formulation for the development of transdermal drug- delivery system of 
diltiazem  hydrochloride.  Transdermal  patches  of  the  drug,  employing 
different ratios of polymers, ethylcellulose (EC); and Povidone (PVP) were 
developed and evaluated  for  the  potential  drug  delivery  using  depilated 
freshly  excised  abdominal  mouse  skin.  The  influence  of  different  film 
compositions on in vitro drug permeation into receptor fluid were studied 
using a modified Franz diffusion cell. The cumulative amount of drug was 
found to be proportional to the square root of time, i.e., Higuchi kinetics. 
From this  study,  it  was  concluded that  the  films  compsed of  Povidone: 
ethylcellulose (1:2) should be selected for the development of transdermal 
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drug-delivery system of diltiazem hydrochloride, using a suitable adhesive 
layer and backing membrane, for potential therapeutic use.
Gopal Rao, M.,76 et.al.,(2001) developed a matrix type transdermal 
drug delivery system of Propranolol hydrochloride using polymers like PVA 
and PVP alone and in combinations. Glycerol was used as the plasticizer 
and tween 80 was used as the permeation enhancer. Along with the physico-
chemical  evaluation  and  in  vitro  drug  diffusion  studies,  the  effect  of 
formulation  variables  such  as  plasticizer  concentration,  film  thickness, 
concentration of  permeation enhancer,  loading dose on weight  variation, 
thickness,  moisture  content,  drug content and in  vitro drug release  were 
studied.  Due  to  the  increase  in  PVP and  plasticizer  concentration,  the 
moisture  content  got  increased.  Increase  in  loading  dose,  permeation 
enhancer and plasticizer concentration, synergistically improved the in vitro 
drug  release  from  the  formulated  patches.  Increasing  the  thickness 
significantly  retarded  the  drug  release.  Accelerated  stability  studies 
indicated that  the formulated patch had adequate shelf  life.  The primary 
skin  irritation  studies  on  animal  and  human  volunteers  revealed  that 
formulated patches were compatible with skin. As the result formulation F13 
PVA: PVP at 4: 1 was found to be an ideal patch.
Gopal Rao, M.,77 et.al.,(2001) developed a matrix type transdermal 
drug  delivery  system  of  verapamil  hydrochloride  using  polymers  like 
cellulose acetate butyrate (CAB) and  polyvinyl pyrrolidone (PVP) alone 
and  in  combinations.  Dibutyl  phthalate  was  used  as  the  plasticizer  and 
Isopropyl myristate was used as the permeation enhancer. Along with the 
physico-chemical evaluation and in vitro drug diffusion studies, the effect 
of formulation variables such as plasticizer concentration, film thickness, 
concentration of  permeation enhancer,  loading dose on weight  variation, 
thickness,  moisture  content,  drug content and in  vitro drug release  were 
62
studied.  Due  to  the  increase  in  PVP and  plasticizer  concentration,  the 
moisture  content  got  increased.  Increase  in  loading  dose,  permeation 
enhancer and plasticizer concentration, synergistically improved the in vitro 
drug  release  from  the  formulated  patches.  Increasing  the  thickness 
significantly  retarded  the  drug  release.  Accelerated  stability  studies 
indicated that  the formulated patch had adequate shelf  life.  The primary 
skin  irritation  studies  on  animal  and  human  volunteers  revealed  that 
formulated patches were compatible with skin. As the result formulation F13 
CAB: PVP at 4: 1 was found to be an ideal patch.
Gopal Rao, M.,78 et.al.,(2000) developed a matrix type transdermal 
drug delivery system of Metoprolol tartrate using polymers like PVA and 
PVP alone and in combinations. Glycerol was used as the plasticizer and 
tween 80 was used as the permeation enhancer. Along with the physico-
chemical  evaluation  and  in  vitro  drug  diffusion  studies,  the  effect  of 
formulation  variables  such  as  plasticizer  concentration,  film  thickness, 
concentration of  permeation enhancer,  loading dose on weight  variation, 
thickness,  moisture  content,  drug content and in  vitro drug release  were 
studied.  Due  to  the  increase  in  PVP and  plasticizer  concentration,  the 
moisture  content  got  increased.  Increase  in  loading  dose,  permeation 
enhancer and plasticizer concentration, synergistically improved the in vitro 
drug  release  from  the  formulated  patches.  Increasing  the  thickness 
significantly retarded the drug release. As the result formulation N2 PVA: 
PVP at 2:1 with 10% glycerol and thickness of 172.73± 4.17 microns and 
loaded dose 4mg/ cm2 was found to be an ideal patch.
Gopal Rao, M.,79 et.al.,(2000) developed a matrix type transdermal 
drug delivery system of Isosorbide dinitrate using polymers like cellulose 
acetate  butyrate  (CAB)  and   polyvinyl  pyrrolidone  (PVP)  alone  and  in 
combinations. Dibutyl phthalate was used as the plasticizer and isopropyl 
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myristate was used as the permeation enhancer. Along with the physico-
chemical  evaluation  and  in  vitro  drug  diffusion  studies,  the  effect  of 
formulation  variables  such  as  plasticizer  concentration,  film  thickness, 
concentration of  permeation enhancer,  loading dose on weight  variation, 
thickness,  moisture  content,  drug content and in  vitro drug release  were 
studied.  Due  to  the  increase  in  PVP and  plasticizer  concentration,  the 
moisture  content  got  increased.  Increase  in  loading  dose,  permeation 
enhancer and plasticizer concentration, synergistically improved the in vitro 
drug  release  from  the  formulated  patches.  Increasing  the  thickness 
significantly  retarded  the  drug  release.  Accelerated  stability  studies 
indicated that  the formulated patch had adequate shelf  life.  The primary 
skin  irritation  studies  on  animal  and  human  volunteers  revealed  that 
formulated patches were compatible with skin. As the result formulation F13 
CAB: PVP at 4: 1 was found to be an ideal patch.
Xu DH.92 et.al.,(1999) studied the synergistic effects of ethosomes 
and chemical enhancers on enhancement of naloxone permeation through 
human skin.  The purpose of  this  study was to  investigate  the  effects  of 
ethosomes, chemical enhancers and their binary combination on the in vitro 
permeability enhancement of naloxone through human skin. Franz diffusion 
cells were used for the percutaneous absorption studies. Propylene glycol 
(PG), N, N-dimethyl formamide (N, N-DMF), N, N-dimethyl acetamide (N, 
N-DMA), dimethyl sulfoxide (DMSO), Azone and polyethylene glycol 400 
(PEG400),  were chosen as the chemical  enhancers.  Naloxone ethosomes 
showed 11.68 times increase in steady-state flux compared to phosphate 
buffered  solution  (PBS).  Ethosomes  in  combination  with  chemical 
enhancers  synergistically  increased (p < 0.05)  in  vitro flux of naloxone. 
Azone 3% + PG7% pretreated in ethosomal form dramatically enhanced the 
skin permeation of  naloxone in vitro compared with ethosomes (steady-
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state flux: 96.75 +/- 5.70 microg x cm (-2) x h (-1) vs 20.56 +/- 1.67 microg 
x cm (-2) x h(-1)). Ethosomal carrier and enhancers accumulated in the skin 
after 24 h were greater than that of PBS.
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OBJECTIVE OF THE PROJECT
Transdermal drug delivery system has been in existence for a long 
time.  The  occurrence  of  systemic  side  effects  with  some  of  these 
formulations is indicative of absorption through skin. A number of drugs 
have been applied to the skin for systemic treatment. In a broad sense, the 
term transdermal delivery system includes all topically administered drug 
formulations  intended  to  deliver  the  active  ingredient  into  the  general 
circulation. The advantages of transdermal drug delivery include its ease of 
use,  patient  compliance,  sustained  drug  delivery,  local  application  and 
safety. Oral medications must pass through the gastrointestinal tract, into 
the  liver-  where  drugs  are  broken  down,  possibly  lowering  their 
effectiveness.  With  the  transdermal  patch,  drugs  enter  directly  into  the 
bloodstream, reducing the risk of gastrointestinal side effects and bypassing 
breakdown by the liver.
In particular the invention relates to the methods and compositions 
for  treating  patients  in  need  of  statin  therapy,  for  example  for 
hyperlipidemia  and  hypercholestorlemia  syndrome,  including  but  not 
limited to those associated with diabetic conditions. Statin drugs also may 
affect the risk of clot formation and therefore risk of heart attack. These 
drugs  also  can  lower  LDL and  contribute  to  lowering  triglyceride-rich 
lipoprotein  levels.   The  methods  of  embodiments  of  this  invention  are 
designed to produce a reduction or elimination of the side effects which 
commonly occur with statin drugs and to permit treatment of patients who 
cannot or do not wish to begin or continue statin therapy due to concomitant 
drug therapies, potential side effects, etc.
One such drug is atorvastatin calcium62, which is a synthetic lipid-
lowering agent and its molecular weight is 1209.42. Atorvastatin is rapidly 
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absorbed  after  oral  administration  and  maximum  plasma  concentrations 
occur within 1 to 2 hours but the absolute bioavailability is approximately 
14%  and  the  systemic  availability  of  HMG-CoA  reductase  inhibitory 
activity is approximately 30%. The low systemic availability is attributed to 
pre-systemic clearance in gastrointestinal mucosa and/or hepatic first-pass 
metabolism. So the objective becomes focused that formulating atorvastatin 
as transdermal patches improves its systemic availability as well ability to 
consistently administer the drug at a zero order rate and the availability to 
remove the drug rapidly from the user in cases of adverse effects, toxicity, 
or  any  other  undesirable  effects.  An additional  advantage  is  increase  in 
patient compliance. Controlled release and efficient bioavailability through 
transdermal patches may results with lowering the dose required per day.
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MATERIALS AND EQUIPMENTS USED
MATERIALS USED:
Table: 2
S.no Materials Grade Source
01 Atorvastatin Calcium Gift sample from Blue 
Cross Laboratories 
Limited.
02 Hydroxy Propyl Methyl 
Cellulose
E50 LV 
premium
Loba Chemie Pvt. Ltd.
03 Ethyl Cellulose 18-22 cp Loba Chemie Pvt. Ltd.
04 Eudragit RS100 Rohm Pharma
05 Glycerine AR S.d fine chemicals
06 Dimethyl Sulfoxide AR Merck Ltd
07 Dimethyl Formamide AR Hi-Pure fine Chem. Ind.
08 Chloroform AR Qualigens Fine Chemicals
09 Methanol AR Qualigens Fine Chemicals
10 Mercury S.d fine chemicals
11 Calcium chloride Anhydrous Qualigens Fine Chemicals
12 Potassium di hydrogen 
phosphate
AR Qualigens Fine Chemicals
13 Sodium hydroxide AR Qualigens Fine Chemicals
14 Sodium chloride AR Qualigens Fine Chemicals
15 TLC plates Merck Ltd.
16 Potassium bromide AR Qualigens Fine Chemicals
17 Benzene AR Qualigens Fine Chemicals
18 Acetic acid AR Qualigens Fine Chemicals
19 Cellophane membrane 0.2µm Sartorius Ltd.
EQUIPMENTS USED
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Table: 3
S.NO EQUIPMENT MODEL/COMPANY
01 Franz Diffusion Cell Fabricated one
02 UV Visible Spectrophotometer Shimadzu UV- 1700
03 FT/ IR Spectrometer FT/ IR JASCO-410
04 Digital balance Shimadzu Electronic Balance
05 Hot air oven Inlab Equipments
06 Magnetic stirrer Remi Equipments
07 Circular mould dishes Fabricated one
08 Laboratory stirrer with variable 
speed control
Remi Motors
09 Vacuum dessicator -
10 Dial caliper Aerospace Electronic Digital 
Micrometer
11 Single pan balance Dhona 200 D
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METHODOLOGY
PREFORMULATION STUDIES
Before the formulation of a drug substance into a dosage form, it is 
essential  that  it  should  be  chemically  and physically  characterized.  Pre-
formulation studies give the information needed to define the nature of the 
drug substance and provide a framework for  the drug combination with 
pharmaceutical excipients in the fabrication of a dosage form.
In the present work,  pre- formulation studies on the compatibility 
between  drug  and  polymer  were  carried  out  using  thin  layer 
chromatography and Infra- Red spectroscopy.
THIN LAYER CHROMATOGRAPHY:
A thin layer chromatography was carried out to study the interaction 
between the drug and polymers. For this the pure drug and its combinations 
with the polymers were subjected to chromatographic studies.
The following TLC system was used-
Precoated TLC plates: Mfg by S.d fine chemicals
Adsorbant Layer : Silica gel G
Layer Thickness : 200µm
Separation Technique: Ascending
Size : 10x 20 cm
Mobile phase : Chloroform:Benzene: Methanol:Aceticacid
                      6         :      3      :        1      :       0.1
Preparation of sample:  a suitable amount of pure drug or equivalent
amount of the samples were dissolved in
chloroform: methanol (1:1) and were used 
for spotting.          
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Amount applied  : 10 µL
Detection : UV chamber.
The Rf values are given in the table: 5 and figure: 5.
FT/ IR spectral studies:
Compatibility studies of the drug and the polymers were carried out 
using  FT/  IR  JASCO-410  spectrometer.  1  part  of  the  sample  is  mixed 
thoroughly with 3 parts of dried potassium bromide and it was compressed 
into transparent, thin pellets. The pellets are then scanned under IR region 
and the spectra were recorded and discussed in the later part.
PREPARATION OF STANDARD GRAPH OF ATORVASTATIN 
CALCIUM: 
STANDARD STOCK SOLUTION 
The stock solution (1mg/ml) of Atorvastatin calcium was prepared in 
methanol68.
SCANNING OF ATORVASTATIN CALCIUM: 
The above-prepared standard stock solution was scanned under UV 
region between 200-  400nm and 241 nm is  found to  be  the  absorption 
maxima wavelength and the same was used for further analysis.
STANDARD PLOT  
With  reference  to  Nagraj64 et.al., who  found  the  linearity  of 
Atorvastatin calcium as 4-22 mcg/ml a series of dilutions were prepared 
from  the  standard  stock  solution  using  phosphate  buffer  pH  7.4.  The 
dilutions  were  made  in  such  a  way  to  obtain  4,  8,  12,  16,  20  mcg/ml 
concentration finally, using phosphate buffer pH 7.4. The absorbances were 
measure  against  the  reagent  blank  using  SHIMADZU  UV  1700 
spectrophotometer at 241nm (table: 10& figure: 13). Calibration graph was 
plotted against respective drug concentration versus absorbances at 241 nm.
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FORMULATION OF TRANSDERMAL PATCHES
GENERAL METHOD OF PREPARATION OF TRANSDERMAL 
PATCHES:
In the present study, matrix type transdermal patches of Atorvastatin 
calcium were prepared by moulding techniques. A flat circular glass moulds 
having diameter 4.5 cm and height of 1 cm with a total surface area of 
15.91cm2 was fabricated for this purpose.
A) PREPARATION OF CASTING SOLUTIONS:
The  casting  solutions  were  prepared  by  dissolving  weighed 
quantities of polymers in a solvent mixture of chloroform and methanol at 
1:1 ratio. The drug, plasticizer and permeation enhancers were then added 
to the various polymer solutions individually and thoroughly mixed to from 
a  homogenous  mixture  (table:  4).  It  was  placed  aside  without  any 
disturbances to allow the entrapped air to bubble out. 
B) PREPARATION OF TRANSDERMAL PATCHES:
About  3  ml  of  casting  solutions  were  pipetted  into  circular  glass 
moulds especially designed to hold contents, which is casted on mercury 
surface. The glass moulds containing the casting solutions were allowed for 
drying at room temperature for 24 hrs and the patches are dried in over at 
40-45° for 30 minutes in order to remove the residual solvents. The patches 
were removed and cut into circular discs with 4.4cm diameter (15.21cm2 
surface area). These patches were wrapped in aluminum foil and stored in 
dessicator for further studies65, 70, 72, 74. 
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Table: 4    COMPOSITIONS OF TRANSDERMAL PATCHES OF ATORVASTATIN CALCIUM
Ingredients T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13 T14 T15 T16 T17 T18 T19 T20 T21
Atorvastatin 
Calcium in 
(mg)
10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
Hydroxyl 
Propyl 
Methyl 
Cellulose in 
Parts
45 4.0 3.5 3.0 2.5 2.0 1.0 4.5 4.0 3.5 3.0 2.5 2.0 1.0
Ethyl 
Cellulose in 
Parts
4.
5
4.
0
3.
5
3.
0
2.
5
2.
0
1.
0
0.
5
1.
0 1.5 2.0 2.5 3.0 4.0
Eudragit 
Rs.100 in 
Parts
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
4.
0 0.5 1.0 1.5 2.0 2.5 3.0 2.0
Glycerol in 
% w/w 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30
DMSO in 
w/w 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20
T1-T7: 10%w/w of EC: ERS100 T8-T14: 5%w/w of HPMC: EC T15-T21: 10%w/w of HPMC: ERS100
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EVALUATION OF TRANSDERMAL PATCHES
The  prepared  patches  were  evaluated  for  their  physico-  chemical 
parameters, in vitro diffusion studies, skin irritation and stability studies83.
PHYSICO- CHEMICAL PARAMETERS:
The matrices were evaluated for the following parameters83, 84, 85, 86, 87, 88.
FILM THICKNESS:
The  thickness  was  measured  at  six  different  places  using  an 
Electronic  Digital  Micrometer  (AEROSPACE-  CHINA)  and  the  mean 
Value was calculated.
DETERMINATION OF AVERAGE WEIGHT AND WEIGHT VARIATION:
As  weight  variation  between  the  formulated  patches  can  lead  to 
difference in drug content and in-vitro behaviour, a study was carried out by 
weighing 6 patches in an electronic balance (table: 6-8). The average weight 
of a patch and its standard deviation was calculated by using the following 
formulas.
Average weight of each patches = total weight of 5 patches/5
Standard deviation  = ∑  x−X 2n−1
Where x = weight of individual patch
X = average weight
n = number of patches
DETERMINATION OF TENSILE STRENGTH:
The instrument, which was designed in our laboratory, was used for 
the measurement of tensile strength. The strip was clamped at the static end 
and was attached to the movable rod on a railing with the help of a clip. The 
weights were gradually added to the pan to increase the pull force till the 
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film was cut. The elongation was determined simultaneously by noting the 
distance traveled by  the  pointer,  before  break of  the  film,  on  the  graph 
paper. The weight required to break the film was noted as the break force 
(table: 6-8). The tensile strength was calculated using Allen’s formula.
TENSILE STRENGTH = BREAK FORCE  x (1 + ∆L )
  a x b        L
Figure 18: Tensile strength apparatus
DETERMINATION OF HARDNESS:
The apparatus designed in our laboratory to study the hardness of the 
strips consists of a wooden stand of 11cms height and top area of 16 X 16 
cm. A small pan was fixed horizontally on one end of the 2 mm thick iron 
rod whose other end is reduced to sharp point. A hole of 0.2 cm diameter 
was made at the center of the top area of wooden stand for supporting the 
pan rod. An electric circuit was made through a 3-volt battery in such a way 
that the bulb lights up only when circuit is completed through the contact of 
the metal plate and the sharp end of the rod. The film was placed between 
the metal plate and the sharp end of the rod. The weights were gradually 
added to the pan, at an interval of 10 seconds for the stabilization of force 
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till the bulb was glown. The final weight was considered as the measure of 
hardness (table: 9).
Figure 18: Hardness apparatus for transdermal patches
DETERMINATION OF PERCENTAGE MOISTURE CONTENT:
Moisture  content  can  influence  the  mechanical  strength  and  drug 
release behaviour of the transdermal therapeutic systems and therefore, in 
the present study determination of the moisture of the formulated patch was 
estimated by keeping the patch under vacuum desiccation until  constant 
weights were obtained (table: 6-8). The percentage moisture content of the 
patch was calculated by the following formula.
              Percentage moisture content =Initial weight- Final weightInitial weight
76
DETERMINATION OF PERCENTAGE MOISTURE UPTAKE:
The weighed films kept in a desiccator at room temperature for 24hrs 
was taken out and exposed to 75% relative humidity (a saturated solution of 
sodium chloride) in a desiccator until a constant weight for the film was 
calculated as the difference between final and initial weight with respect to 
initial weight (table: 6-8).
Percentage moisture uptake =final weight- initial weightfinal weight
DETERMINATION OF DRUG CONTENT:
A formulated patch having 15.21cm2 area was cut into small pieces 
and  transferred  into  a  graduated  glass  stoppered  flask,  which  contained 
100ml  of  mixture  of  chloroform  and  methanol  in  the  ratio  of  1:1, 
maintained at 45-50˚C. It was closed and shaked vigorously for 24 hours 
period in a shaker. The solution was filtered and the amount of drug present 
in  the  filterate  was  determined  by  using  SHIMADZU  UV-1700 
spectrophotometer at 241nm. Similarly, blank solution was prepared using a 
dummy patch. The procedure was carried out in duplicate to determine the 
drug  content.  The  following  procedure  was  carried  out  induplicate  to 
determine the drug content89 (table: 6-8).
PROCEDURE FOR IN-VITRO DRUG RELEASE STUDIES:
In vitro permeation studies were performed by using Franz diffusion 
cell. It consists of a donor compartment and a receptor compartment. The 
cellulose membrane84 was mounted between the donor compartment and 
receptor compartment of the diffusion cell.  The formulated patches were 
placed over the membrane. The receptor compartment of the diffusion cell 
was filled with phosphate buffer PH 7.4. The whole assembly was fixed on 
a  magnetic  stirrer,  and  the  solution  in  the  receptor  compartment  was 
constantly  and continuously  stirred  using  magnetic  bead at  50  rpm;  the 
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temperature  was maintained at  37±10C. The samples  were  withdrawn at 
different time intervals and analyzed for drug content. The receptor phase 
was replenished with an equal volume of phosphate buffer at each sample 
withdrawal. The cumulative percentage release of drug permeated per cm2 
of patches were plotted against time (table: 11-16& figure: 14-16).
Figure: 4 Franz Diffussion Cell
PRIMARY SKIN IRRITATION STUDIES
Patches were applied to the shaved skin on the backs of albino rats 
and secured using adhesive tape. On one side of the back, control patch and 
on  other  side  an  experimental  patches  were  secured.  The  animals  were 
observed for any sign of erythema or oedema for a period of 24 hours65, 84.
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STABILITY STUDIES
To any rational design and evaluation of dosage forms of drugs the 
stability of the active component must be a major criteria in determining 
their acceptance or rejection. Drugs instability by a change in the physical 
appearance color, odor, taste or texture of the formulation whereas in other 
instances chemical changes may occur which are not self-evident and may 
be ascertained through chemical analysis. Scientific data pertaining to the 
stability of a formulation leads to the prediction of the expected shelf life of 
the proposed product and when necessary to the reformulation of the dosage 
form.
Hence    to assess the stability the selected films were kept at room 
temperature and at 40ºC over a period of 45 days. Patches were evaluated at 
15th,  30th,  45th day  for  their  physico-chemical  properties  and  in  vitro 
diffusion studies.
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RESULTS AND DISCUSSION
Transdermal  drug  delivery  system  of  Atorvastatin  calcium  was 
developed  using  polymers  like  HPMC,  EC,  and  ERS100;  employing 
glycerine as plasticizer and DMSO as the permeation enhancer. Formulated 
21 patches were subjected to physico- chemical evaluation such as physical 
appearance, weight variation, thickness,  % moisture content,  % moisture 
uptake,  tensile  strength,  hardness  and  drug  content.  The  in  vitro  drug 
release  studies  across  cellulose  membrane  were  conducted  and  the  best 
formulations where subjected to stability studies.
COMPATIBILITY STUDIES
The compatibility  studies  confirmed that  the  absence of  chemical 
interaction  between  the  drug  and  polymers.  The  physico  chemical 
parameters were evaluated.
Thin layer chromatography
TLC for the pure drug and in combination with the polymers were 
performed (fig:5) and the Rf values were reported in the table:5 The Rf 
values indicate the absence of chemical interaction between the drug and 
the polymers.
FT/ IR spectral studies
Compatibility  studies  of  the  drug  and  the  polymers  were  carried 
using JASCO FT/ IR spectrometer and the spectras were given in the fig:6-
12. The spectra obtained from the mixture of polymers and drug was found 
to be matching with the spectra of the pure drug. There was no appearance 
or disappearance of any characteristic peaks, which confirmed the absence 
of chemical interaction between the drug and polymer.
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Thin layer chromatogram details
Figure:5
Table:5
S.NO SAMPLE Rf VALUE
1 Drug 0.48
2 Drug+ HPMC+ EC 0.47
3 Drug+ HPMC+ ERS100 0.47
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Figure: 6   IR Spectrum of Atorvastatin calcium
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Figure: 7  IR Spectrum of ERS100
Figure: 8  IR Spectrum of EC
83
84
Figure: 9  IR Spectrum of HPMC
85
Figure: 10  IR Spectrum of Drug + HPMC + EC
86
Figure: 11  IR spectrum of Drug + EC + ERS100
87
Figure: 12  IR Spectrum of Drug + HPMC + E RS100
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Physico- Chemical parameters
Twenty-one patches  of  Atorvastatin  calcium loaded with different 
ratios of HPMC, EC and ERS100 were prepared by moulding technique. 
The prepared patches were evaluated for physico chemical parameters and 
in vitro drug release behaviour.
The determination of the average weight of patch, having 15.21cm2 
surface area showed a significant change between the patches prepared with 
different polymer ratios.  The average weight of the patches T1- T21 were 
given in  the  table:  6-8.  Among the  21 patches,  T1-  T7 showed a  higher 
average weight compared to other patches and T15-T21 showed less weight. 
This increase in weight of T1- T7 patches is due to usage of 10%w/w of 
polymers whereas in other formulations only 5%w/w polymers were used.
There was no significant change in the thickness of the patches (T1- 
T21),  which  was  determined  by  aerospace  digital  electronic  micrometer 
(table: 6-8). This indicates that the patches were uniform and reproducible.
The results of moisture content (table: 6-8) of the coded transdermal 
patches (T8-T14) showed a marked difference in the moisture content. The 
patches T8-T21 showed higher moisture content and moisture uptake, which 
was due to the higher content of hydrophilic polymer, HPMC. The patches 
T1 to T7 showed less moisture content and uptake because of the blend of 
both hydrophobic polymers.
Tensile strength (table: 6-8) is found to be higher for the patches T8-
T15 when compared to other patches and hardness (table: 9) is found to be 
low for the patches T8-T15 when compared to other patches.
All the patches showed uniform drug content, which was determined 
using SHIMADZU UV- 1700 spectrophotometer (table: 6-8).
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Table: 6 Physico-chemical parameters of the formulated transdermal patches of Atorvastatin calcium- T1 toT7
Formulation 
Code
Polymer 
Ratio
EC: 
ERS100
Physical 
Appearance
Weight 
Variation
(grams)
Thickness
(mm)
Tensile 
Strength
(kg/cm2)
Moisture 
Content 
(%)
Moisture 
Uptake
(%)
Drug 
Content
(mg/cm2)
T1 4.5:0.5
Translucent, 
Flexible, 
Smooth.
0.592±0.028 0.175±0.009 0.946 3.31±0.18 5.43±0.01 0.5969
T2 4:1
Translucent, 
Flexible, 
Smooth.
0.566±0.017 0.184±0.013 0.927 2.77±0.16 4.97±0.004 0.547
T3 3.5:1.5
Translucent, 
Flexible, 
Smooth.
0.474±0.019 0.147±0.003 0.945 2.59±0.43 4.05±0.001 0.6449
T4 3:2
Translucent, 
Flexible, 
Smooth.
0.500±0.009 0.152±0.008 0.943 2.48±0.90 3.77±0.009 0.5437
T5 2.5:2.5
Translucent, 
Flexible, 
Smooth.
0.497±0.01 0.167±0.006 0.895 2.43±0.66 3.15±0.01 0.6219
T6 2:3
Translucent, 
Flexible, 
Smooth.
0.502±0.008 0.195±0.018 0.839 2.09±0.49 2.64±0.02 0.6002
T7 1:4
Translucent, 
Flexible, 
Smooth.
0.525±0.001 0.056±0.043 0.890 1.24±0.57 1.99±0.025 0.5739
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Table No: 7 Physico-chemical parameters of the formulated transdermal patches of Atorvastatin calcium- T8 to T14
Formulation 
Code
Polymer 
Ratio
HPMC: 
EC
Physical 
Appearance
Weight 
Variation
(grams)
Thickness
(mm)
Tensile 
Strength
(kg/cm2)
Moisture 
Content
(%)
Moisture 
Uptake
(%)
Drug 
Content
(mg/cm2)
T8 4.5:0.5
Transparent, 
Flexible, 
Smooth
0.322±0.006 0.157±0.015 1.755 8.75±0.015 10.12±0.006 0.5634
T9 4:1
Transparent, 
Flexible, 
Smooth
0.322±0.006 0.120±0.07 1.645 7.55±0.007 9.88±0.009 0.5456
T10 3.5:1.5
Transparent, 
Flexible, 
Smooth
0.327±0.008 0.119±0.001 1.599 7.09±0.017 8.98±0.013 0.5391
T11 3:2
Transparent, 
Flexible, 
Smooth
0.304±0.005 0.102±0.008 1.555 6.63±0.002 8.17±0.016 0.5128
T12 2.5:2.5
Transparent, 
Flexible, 
Smooth
0.284±0.008 0.084±0.016 1.60 5.88±0.01 7.76±0.035 0.5542
T13 2:3
Transparent, 
Flexible, 
Smooth
0.293±0.005 0.134±0.005 1.504 5.14±0.03 6.85±0.048 0.6101
T14 1:4
Transparent, 
Flexible, 
Smooth.
0.286±0.008 0.135±0.006 1.551 4.36±0.009 5.67±0.009 0.6239
Table No: 8 Physico-chemical parameters of the formulated transdermal patches of Atorvastatin calcium- T15 to T21
Formulation Polymer Physical Weight Thickness Tensile Moisture Moisture Drug 
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Code
Ratio
HPMC: 
ERS100
Appearance Variation(grams) (mm)
Strength
(kg/cm2)
Content
(%)
Uptake
(%)
Content
(mg/cm2)
T15 4.5:0.5
Transparent, 
Flexible, 
Smooth
0.283±0.01 0.152±0.009 1.360 6.09±0.24 7.51±0.017 0.6134
T16 4:1
Transparent, 
Flexible, 
Smooth
0.318±0.001 0.150±0.008 1.247 5.77±0.009 6.93±0.083 0.5654
T17 3.5:1.5
Transparent, 
Flexible, 
Smooth
0.310±0.001 0.112±0.017 1.389 4.98±0.017 6.22±0.037 0.5456
T18 3:2
Transparent, 
Flexible, 
Smooth
0.304±0.004 0.167±0.006 1.338 4.08±0.038 5.95±0.009 0.6173
T19 2.5:2.5
Transparent, 
Flexible, 
Smooth
0.337±0.009 0.188±0.016 1.287 3.56±0.061 5.28±0.044 0.5765
T20 2:3
Transparent, 
Flexible, 
Smooth
0.289±0.01 0.150±0.008 1.241 2.83±0.17 4.53±0.006 0.5351
T21 1:4
Transparent, 
Flexible, 
Smooth.
0.361±0.02 0.144±0.003 1.124 2.14±0.19 3.45±0.002 0.6213
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Table: 9   HARDNESS PROFILE OF THE FORMULATED 
PATCHES-T1 to T21
Formulation 
code
Hardness 
(grams)
Formulation 
code
Hardness 
(grams)
Formulation 
code
Hardness 
(grams)
T1 175 T8 12.76 T15 44
T2 172 T9 16.59 T16 49
T3 170 T10 19.33 T17 54
T4 169 T11 20.33 T18 47
T5 155 T12 21.20 T19 51
T6 134 T13 19.32 T20 54
T7 110 T14 18.02 T21 60
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In vitro drug release studies
The in vitro drug release studies carried out indicate the influence of 
polymers on the release of drug. The cumulative release of drug (mg/cm2) 
and  cumulative  percentage  release  of  T1-  T21 patches  over  24  hrs  were 
determined and are summarized in table:11-16 and graph: 14-16.
The increase in HPMC concentration resulted in increase in drug 
released from T8 patch, whereas T1 showed lower drug release because both 
the polymers EC and ERS100 were hydrophilic. Patch T15 showed lesser 
release than T8 because of the presence of hydrophobic polymer ERS100.
Skin irritation studies 
The skin irritation study reveals that the drug loaded and unloaded 
patches didn't cause any noticeable signs of irritation or oedema on albino 
rat's  skin,  indicating  the  skin  compatibility  of  drug  as  well  as  polymer 
matrix.
Stability studies
The  stability  studies  indicate  there  was  no  change  in  physico-
chemical  and  in  vitro  drug  release  studies  for  T1,  T8,  and  T15 patches 
(table:17-19 & graph: 17).
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Table: 10   Calibration graph of Atorvastatin calcium
SI. No. Concentration mcg/ml Absorbance @ 241nm
1. 4 0.155
2. 8 0.313
3. 12 0.468
4. 16 0.621
5. 20 0.774
Figure: 13 Calibration graph of Atorvastatin calcium
0
0.2
0.4
0.6
0.8
1
0 4 8 12 16 20
Conc (mcg/ml)
A
bs
or
ba
nc
e 
@
 2
41
 n
m
95
Table: 11 Cumulative amount release of atorvastatin calcium transdermal patches formulated by employing 
polymers like EC & ERS100: T1 TO T7
Polymer 
ratio 
EC:ERS 
100
Cumulative amount release (mg/cm2) of drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 9 h 10 h 24 h
4.5:0.5 0.1058 0.0161 0.0193 0.0230 0.0271 0.0446 0.0501 0.0552 0.0612 0.0662 0.1546
4:1 0.0087 0.0110 0.0142 0.0179 0.0225 0.0253 0.0294 0.0354 0.0391 0.0465 0.1298
3.5:1.5 0.0092 0.0119 0.0133 0.0161 0.0197 0.0230 0.0276 0.0326 0.0368 0.0409 0.1159
3:2 0.0059 0.0110 0.0119 0.0170 0.0216 0.0243 0.0276 0.0322 0.0354 0.0386 0.1077
2.5:2.5 0.0023 0.0055 0.0078 0.0115 0.0152 0.0188 0.0225 0.0266 0.0308 0.0335 0.1022
2:3 0.0013 0.0036 0.0087 0.0124 0.0156 0.0197 0.0230 0.0262 0.0294 0.0326 0.0911
1:4 0.0005 0.0023 0.0059 0.0096 0.0119 0.0161 0.0197 0.0234 0.0262 0.0299 0.0690
Table: 12 Cumulative percentage release of atorvastatin calcium transdermal patches formulated by 
employing polymers like EC & ERS100: T1 TO T7
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Polymer 
ratio 
EC:ERS 
100
Cumulative percentage release of drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 9 h 10 h 24 h
4.5:0.5 1.77 2.69 3.23 3.85 4.55 7.47 8.40 9.25 10.25 11.10 25.90
4:1 1.59 2.01 2.60 3.28 4.12 4.62 5.38 6.47 7.15 8.49 23.72
3.5:1.5 1.42 1.85 2.06 2.49 3.06 3.56 4.28 5.06 5.70 6.35 17.98
3:2 1.10 2.03 2.20 3.13 3.97 4.48 5.07 5.92 6.51 7.11 19.80
2.5:2.5 0.37 0.88 1.25 1.84 2.44 3.03 3.62 4.29 4.95 5.40 16.42
2:3 0.23 0.61 1.45 2.07 2.60 3.29 3.83 4.37 4.90 5.44 15.18
1:4 0.08 0.40 1.04 1.68 2.08 2.80 3.44 4.08 4.57 5.21 12.02
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Figure: 14 INVITRO RELEASE PROFILE OF PATCHES T1 TO T7
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Table: 13 Cumulative amount release of atorvastatin calcium transdermal patches formulated by 
employing polymers like HPMC & EC: T8 TO T14
Polymer 
ratio 
HPMC:EC
Cumulative amount release (mg/cm2) of drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 9 h 10 h 24 h
4.5:0.5 0.0262 0.0349 0.0579 0.0685 0.0814 0.0902 0.1031 0.1380 0.1592 0.1739 0.4832
4:1 0.0211 0.0326 0.0464 0.0625 0.0786 0.0837 0.0984 0.1090 0.1491 0.1702 0.4556
3.5:1.5 0.0117 0.0331 0.0460 0.0520 0.0639 0.0736 0.0828 0.0902 0.1040 0.1187 0.4086
3:2 0.0138 0.0308 0.0414 0.0511 0.0598 0.0662 0.0745 0.0851 0.1003 0.1109 0.3835
2.5:2.5 0.0092 0.0142 0.0308 0.0404 0.0492 0.0612 0.0713 0.0768 0.0934 0.0952 0.356
2:3 0.0055 0.0110 0.0138 0.0340 0.0442 0.0547 0.0598 0.0823 0.0856 0.0943 0.348
1:4 0.0018 0.0027 0.0216 0.0312 0.0377 0.0478 0.0556 0.0648 0.0740 0.0860 0.3285
Table: 14 Cumulative percentage release of atorvastatin calcium transdermal patches formulated by 
employing polymers like HPMC & EC: T8 TO T14
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Polymer 
ratio 
HPMC:EC
Cumulative percentage release of drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 9 h 10 h 24 h
4.5:0.5 4.65 6.20 10.29 12.17 14.45 16.01 18.29 24.50 28.26 30.87 85.77
4:1 3.88 5.98 8.51 11.47 14.42 15.35 18.05 19.99 27.32 31.21 83.56
3.5:1.5 2.21 6.14 8.53 9.64 11.8 13.65 15.36 16.73 19.29 22.02 75.80
3:2 2.69 6.01 8.07 9.96 11.66 12.92 14.54 16.60 19.56 21.62 74.78
2.5:2.5 1.66 2.57 5.56 7.30 8.88 11.64 12.87 13.86 16.85 17.19 64.27
2:3 0.95 1.81 2.26 5.58 7.24 8.97 9.80 13.50 14.03 15.46 57.02
1:4 0.29 0.44 3.46 5.01 6.04 7.67 8.92 10.40 11.87 13.79 52.66
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Figure: 15 INVITRO RELEASE PROFILE OF PATCHES T8 TO T14
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Table: 15 Cumulative amount release of Atorvastatin calcium transdermal patches formulated by 
employing polymers like HPMC & ERS100: T15 TO T21
Polymer 
ratio 
HPMC:ERS 
100
Cumulative amount release (mg/cm2) of drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 9 h 10 h 24 h
4.5:0.5 0.0188 0.0294 0.0464 0.0570 0.0667 0.0740 0.0828 0.0920 0.1003 0.1182 0.2927
4:1 0.0119 0.0253 0.0354 0.0409 0.0511 0.0662 0.0736 0.0824 0.0888 0.0957 0.2706
3.5:1.5 0.0152 0.0230 0.0262 0.0359 0.0492 0.0612 0.0708 0.0759 0.0860 0.0948 0.2623
3:2 0.0096 0.0156 0.0248 0.0359 0.0409 0.0570 0.0639 0.0708 0.0768 0.0842 0.2402
2.5:2.5 0.0069 0.0101 0.0129 0.0225 0.0289 0.0368 0.0474 0.0520 0.0607 0.0732 0.2236
2:3 0.0041 0.0073 0.0115 0.0142 0.0239 0.0308 0.0382 0.0465 0.0570 0.0667 0.1795
1:4 0.0018 0.0050 0.0101 0.0128 0.0188 0.0248 0.0345 0.0428 0.0566 0.0589 0.162
Table: 16 Cumulative percentage release of Atorvastatin calcium transdermal patches formulated by 
employing polymers like HPMC & ERS100: T15 TO T21
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Polymer 
ratio 
HPMC:ERS 
100
Cumulative percentage release of drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 9 h 10 h 24 h
4.5:0.5 3.07 4.80 7.57 9.30 10.88 12.07 13.50 15.00 16.35 19.28 47.71
4:1 2.11 4.47 6.26 7.24 9.03 11.72 13.02 14.57 15.71 16.93 47.86
3.5:1.5 2.78 4.21 4.80 6.57 9.02 11.21 12.99 13.92 15.77 17.37 48.08
3:2 1.56 2.53 4.02 5.81 6.63 9.24 10.36 11.48 12.45 13.64 38.92
2.5:2.5 1.19 1.75 2.23 3.91 5.03 6.38 8.22 9.02 10.54 12.69 38.79
2:3 0.77 1.37 2.15 2.66 4.47 5.97 7.14 8.68 10.66 12.47 33.54
1:4 0.29 0.81 1.62 2.07 3.03 4.00 5.55 6.88 8.15 9.48 26.22
 
Figure: 16  INVITRO RELEASE PROFILE OF PATCHES T15 TO T21
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Table:17  Physico-chemical evaluation of the developed transdermal patch (t1) of atorvastatin calcium 
during the stability studies at 40ºC
Time 
in 
days
Physical 
Appearance
Weight 
Variation
(grams)
Thickness
(mm)
Moisture 
Content 
(%)
Moisture 
Uptake
(%)
Drug 
Content
(mg/cm2)
Cumulative 
amount 
release 
(mg/cm2)  at 
24 h
Cumulative 
percentage 
release at 24 
h
0
Translucent, 
Flexible, 
Smooth
0.589±0.012 0.178±0.005 3.05±0.009 5.29±0.025 0.5864 0.1546 26.36
15 No change 0.592±0.014 0.180±0.007 3.12±0.015 5.75±0.019 0.5862 0.1553 26.49
20 No change 0.590±0.009 0.181±0.005 3.17±0.010 5.93±0.013 0.5860 0.1539 26.26
45 No change 0.594±0.011 0.184±0.009 3.21±0.011 6.01±0.028 0.5965 0.1525 25.56
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Table:18  Physico-chemical evaluation of the developed transdermal patch (t8)  of atorvastatin calcium 
during the stability studies at 40ºC
Time 
in 
days
Physical 
Appearance
Weight 
Variation
(grams)
Thickness
(mm)
Moisture 
Content 
(%)
Moisture 
Uptake
(%)
Drug 
Content
(mg/cm2)
Cumulative 
amount 
release 
(mg/cm2)  at 
24 h
Cumulative 
percentage 
release at 24 
h
0
Transparent, 
Flexible, 
Smooth
0.322±0.006 0.157±0.015 8.75±0.015 10.12±0.006 0.5634 0.4832 85.77
15 No change 0.327±0.015 0.158±0.009 8.81±0.005 10.41±0.014 0.5637 0.4835 85.77
20 No change 0.330±0.009 0.161±0.004 8.97±0.03 10.73±0.023 0.5628 0.4828 85.78
45 No change 0.383±0.018 0.165±0.002 9.35±0.027 11.24±0.025 0.5619 0.4818 85.74
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Table:19  Physico-chemical evaluation of the developed transdermal patch (t15) of atorvastatin calcium during the 
stability studies at 40ºC
Time 
in 
days
Physical 
Appearance
Weight 
Variation
(grams)
Thickness
(mm)
Moisture 
Content 
(in %)
Moisture 
Uptake
(%)
Drug 
Content
(mg/cm2)
Cumulativ
e amount 
release 
(mg/cm2) 
at 24 h
Cumulative 
percentage 
release at 
24 h
0 Transparent, 
Flexible, 
Smooth
0.283±0.015 0.452±0.009 6.09±0.24 7.51±0.017 0.6134 0.2927 47.71
15 No change 0.291±0.023 0.154±0.016 5.98±0.004 7.71±0.12 0.5982 0.2903 48.52
20 No change 0.299±0.017 0.147±0.31 6.25±0.009 7.98±0.14 0.6121 0.2875 46.96
45 No change 0.303±0.028 0.15±0.042 6.92±0.17 8.32±0.25 0.6104 0.2821 46.21
Figure:17 Comparative cumulative percentage release of transdermal patches T1, T8 and T15 during stability studies at 40ºC
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SUMMARY AND CONCLUSION
An  attempt  to  develop  transdermal  therapeutic  system  for 
Atorvastatin  calcium using polymers  like  HPMC, EC,  and ERS100 was 
carried out for the purpose of attaining maximum bioavailability by tress 
passing pre-systemic hepatic metabolism.
The compatibility studies using TLC and IR spectral studies revealed 
the absence of interaction between the drug and the polymer.
The  formulated  patches  were  evaluated  for  the  physico-chemical 
parameters, in vitro drug release studies, skin irritation studies and stability 
studies.
The patches showed a significant variation in their average weight, 
which might be due to the variation in the proportions of polymers used. 
There was no significant change observed in the thickness of all the twenty-
one patches.
The percentage moisture content and percentage moisture uptake is 
found  to  be  high  for  the  patches  formulated  with  HPMC:EC  when 
compared to the patches formulated with HPMC:ERS100 and EC:ERS100. 
The reason behind the screen might be the higher proportions of hydrophilic 
polymer,  HPMC  along  with  EC;  whereas  patches  with  HPMC:ERS100 
combination shows lesser moisture content and moisture uptake because of 
the highly hydrophobic polymer, ERS100.
For the patches with HPMC:EC tensile strength was found to be high 
and hardness was found to be low when compared to other patches which 
might be due to the nature of the polymers.
All the patches showed uniform drug content.
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The formulations T8-T14 showed a better in vitro drug release profile 
across the cellulose membrane, when compared to the other formulations. 
This might be attributed to the nature of polymer; plasticizers used and even 
the permeation enhancer.
The  skin  irritation  studies  using  albino-rats  revealed  no  signs  of 
irritation or oedema, which confirms the skin compatibility of both the drug 
loaded and plain patches.
As far the above results where concerned formulations T1, T8, and T15 
where selected and subjected for stability studies at room temperature and 
at 40ºC for a period of 45 days. The stability studies results signified that 
the formulated patches possess adequate shelf life till 45 days. 
Since the results are encouraging for the formulation T8, the proper 
technique should be applied for commercial  and mass production of the 
same formulation.
However long term pharmacokinetic and pharmacodynamic studies 
should be undertaken to establish the usefulness of these patches.
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